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ABSTRACT 
THAO VO:  DDE and PCBs: intra-individual changes, correlations, predictors and role in 
timing of menopause 
(Under the direction of David Richardson) 
 
Dichlorodiphenyldichloroethane (DDE) and polychlorinated biphenyls (PCBs) have 
been suggested to affect the timing of menopause.  However, results from studies on 
DDE/PCBs and age at menopause have been inconsistent and may be limited by exposure 
assessment at widely divergent ages, remote from the time of etiologic relevance.  Attempts 
to estimate measures at a common and etiologically appropriate age have been limited by the 
paucity of data on the predictors of long-term changes in organochlorines.  Understanding the 
dynamics of individual body burdens of these organochlorines and the factors that predict 
them would improve exposure assessment, and determining whether DDE/PCBs affect age at 
menopause would contribute to the knowledge of their public health significance.    
Data were collected from 512 participants from a 1978-1982 baseline study and a 
2003-2004 follow-up study.  Baseline and follow-up organochlorine measures from 123 
participants were used to characterize the intra-individual changes and predictors of change 
in DDE/PCB levels, in order to provide a model for exposure estimation.  Interview and 
ovarian hormone data at follow-up were used to classify menopausal status and define age at 
menopause, and the effect on timing of menopause from DDE/PCB exposures, estimated at 
age 40, was evaluated. 
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Serum DDE and PCBs dramatically declined (median drop of 84% and 55%, 
respectively) over the follow-up period.  Baseline levels were strongly correlated with and 
predictive of follow-up levels (Spearman correlations (rs): 0.72 for DDE; 0.43 for PCBs).  
Prediction of follow-up PCBs substantially improved with data on initial concentration, 
lactation duration, baseline body mass index, and percent change in body fat (rs= 0.75 
between predicted and actual follow-up levels), whereas DDE prediction improved slightly 
(rs= 0.83).  Effect estimates for age at menopause were inconsistent across organchlorine 
categories (compared to the lowest exposure category, menopause occurred -0.02, 0.4, 0.7, -
0.3 years later across ascending categories of DDE, and -0.4, 0.4, 0.8, and 0.6 years later 
across PCB categories).      
Results suggest a single organochlorine measure provides considerable information 
on relative ranking at distant times and prediction is improved with data on a few easily 
collected variables.  However, the data provide no evidence for an effect of DDE/PCBs on 
age at menopause.   
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 1. BACKGROUND AND SIGNIFICANCE 
 
This chapter is organized into three sections pertaining to organochlorines, natural 
menopause, and the significance and implications of the proposed research.  Section 1.1 
begins with an overview of DDT/DDE and PCBs and discusses their use, biologic properties, 
reported health effects, human exposures and changes to those exposures.  The goals of the 
research on the dynamics of these organochlorines were to evaluate the 1) intra-individual 
changes and 2) correlations in serial measures of p,p’-DDE and PCBs, as well as 3) develop a 
model for the prediction/estimation of organochlorine levels based on literature on the 
predictors of DDE/PCBs.  Sub-sections 1.1.3 and 1.1.4 summarizes the epidemiologic studies 
pertaining to intra-individual changes and correlations in DDE and PCB measures, 
respectively.  The last two subsections (1.1.5 and 1.1.6) begins with an overview of the 
literature on the predictors of a single measure of DDE and PCBs and leads into studies of 
the predictors of organochlorine change—the latter of primary relevance to predictive 
modeling.     
Section 1.2 focuses on natural menopause and begins with an introduction into its 
epidemiology and definition.  The goal of the research on menopause is to determine whether 
p,p’-DDE and PCBs affect the timing of menopause.  Subsection 1.2.2 discusses the factors 
that have been associated with the timing of menopause and subsection 1.2.3 focuses in on 
the role of DDE and PCBs on age at menopause. 
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Section 1.3 provides an overview of the findings and limitations of previous studies 
on the temporal changes, predictors, and possible role of DDE and PCBs in the timing of 
menopause, as well as the goals and implications of the proposed research to address some of 
the limitations.   
 
1.1 ORGANOCHLORINES: DDE AND PCBS 
1.1.1  DDT and DDE: Changes in use and exposures 
Dichlorodiphenyltrichloroethane (DDT) was widely used as a pesticide in the United 
States starting in the 1940s (FIGURE 1.1).  In 1972, DDT was banned from agricultural 
applications in the United States, and thereafter, in many other parts of the world, as a result 
of observed toxic effects in wildlife [1].  Today, DDT is still used for emergency or public 
health purposes in many countries for the prevention of vector-borne diseases, such as 
malaria.   
Technical grade DDT is a mix of primarily isomers p,p’(para-para)-DDT (85%), and 
to a lesser extent, o,p’ (ortho-para)-DDT and o,o’ (ortho-ortho)-DDT [2].  For the remainder 
of this document, DDT will refer to the sum of all DDT isomers and metabolites, whereas 
DDE will refer to p,p’-DDE, unless otherwise noted.   
o,p’-DDT is considered weakly estrogenic and exposure occurs primarily in 
occupational settings, whereas exposure of the general population to p,p’-DDT and its 
metabolite, p,p’-DDE, occurs primarily via dietary intake [3].  p,p’-DDT is more readily 
degraded and excreted than DDE, which has a biologic half-life in humans of over 7 to more 
than 10 years [2, 4-6].   
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p,p’-DDT is reported to have neurotoxic [2] and carcinogenic [7] properties, while 
p,p’-DDE has anti-androgenic effects [8].  These properties prompted studies of their 
potential effects on cancer [9-11], neurodevelopment [12], and reproductive outcomes, such 
as spontaneous abortion [13, 14], and age at menopause [15, 16].  However, clear 
associations have not been established.   
Upon introduction into the environment, DDT and DDE become immobilized in the 
soil and can be transported long distances via water or volatilization into the atmosphere—
hence, their ubiquity in the environment and exposure to humans worldwide [1, 17, 18].  
DDT use increased significantly until 1959, steadily declined until 1972, and then markedly 
dropped with its agricultural ban.  A concomitant change in environmental concentrations 
and exposure to DDT and DDE ensued, with the predominant route of exposure via diet.  In 
the Food and Drug Administration Total Diet Studies estimated average adult intakes of 
DDT from consumption of meat, fish, poultry, and dairy products declined from 240 
ug/person/day in 1970 to 0.97 ug/person/day in 1986-91, corresponding to decreasing levels 
in foodstuffs during the same time period [1].  The sources of exposure and the 
corresponding human tissue levels varies with age, with infants having higher levels due 
primarily to ingestion of pesticide-rich foods (breast milk) and their having lower body fat 
content, and adults acquiring DDE primarily through fish and meat consumption [3]. 
Data from an annual tissue repository of surgical patients and autopsied cadavers, 
gathered by the Environmental Protection Agency in the National Human Adipose Tissue 
Survey (NHATS), reveal a steady decline in lipid-adjusted adipose tissue DDT from a 
geometric mean of 8 ppm in 1970 to 2 ppm in 1983 [19].  A similar decline in mean total 
DDT in human breastmilk can be seen worldwide, as evidenced by numerous cross-sectional 
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population studies [17, 20].  In the United States and Canada, the gradual decrease in the 
1960s became progressively sharper in 1975, following their bans [18].  Despite the drop in 
environmental and human tissue levels, exposure, particularly to DDE, is ongoing due to 
their accumulation and continued presence in the environment.   
 
1.1.2 PCBs: Changes in use and exposures 
In the United States, commercial use of PCBs, marketed under the name Arochlor, 
was widespread from 1929 until 1977, when production was banned, except in totally closed 
systems.  This ban was enacted because of concerns about their persistence and accumulation 
in the environment, and potential for causing toxic effects.  Due to their chemical stability, 
they were used as plasticizers, coolants and lubricants in transformers and capacitors, surface 
coating and adhesives and other applications [21].  PCBs are produced by chlorinating the 
biphenyl structure at one or more of the 10 positions labeled 2 to 6 and 2’ to 6’ (FIGURE 
1.2).  The various number and structural arrangements (i.e. ortho-, para-, meta-) of chlorine 
atoms on the biphenyl ring confer 209 different PCB compounds, referred to as congeners 
[22].  Isomers are PCBs that have the same number of chlorine atoms but differing 
arrangement of the chlorines.   
PCB congeners most often detected in human tissues have high molecular weights [2, 
3, 23], including PCB-118, 138, 153 and 180 [24-27].  Higher molecular weight congeners 
are generally resistant to degradation (having half lives of  ~3-24 years) [28-31] and are fairly 
correlated with one another [3, 32].  PCB-153, being the predominant congener, has been 
used as a marker of exposure for the other PCBs.   
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Fish and meat consumption are the major sources of adult PCB exposure, with 
secondary exposure via inhalation of contaminated air [23].  Children acquire additional 
exposure via mother’s milk.  Exposure to lower molecular weight PCBs occurs primarily in 
occupational settings.    
PCBs congeners  possess broad biologic properties, including both estrogenic and 
anti-estrogenic effects, activation of the ryanodine-sensitive calcium channels as well as 
toxicity similar to 2,3,7,8-tetrachlorobibenzodioxin (2,3,7,8-TCDD), which is the most toxic 
of the non-pesticide organochlorines [2, 33, 34].  Much literature has been published on the 
latter, with TCDD exerting its effect by interacting with the aryl hydrocarbon receptor (Ah) 
receptor, thereby inducing the gene expression of metabolic enzymes, such as cytochrome 
P450, CYP1A1 and CYP1A2 [35, 36].  As determined by their toxic equivalence (TEQ), a 
measure of PCBs toxicity relative to TCDD, coplanar PCBs, chlorinated at both the para 
(4,4’)  positions and two or more meta positions (3,5,3’ and 5’), have the most potent dioxin-
like activity, whereas mono-ortho-substituted PCBs are  less potent [25, 36].     
 Dioxins cause chloracne and liver abnormalities in humans and are linked to other 
adverse health effects [37, 38].  Occupational exposure studies have consistently associated 
PCBs with abnormal liver function tests and chloracne [39-41].  Prenatal PCB exposure may 
also have effects on neurologic development and thyroid function [42-44].  Most 
epidemiologic data on health and PCBs address exposure to total PCBs, rather than specific 
congeners.  There are fairly high correlations between the various PCB congeners [3, 45], 
making it difficult to draw conclusions about causal relationships between body burden of 
individual compounds and disease. 
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Environmental levels of PCBs have declined most precipitously in the late 1970s to 
mid-1980s, corresponding to the timeframe when regulatory controls were imposed on PCB 
use [46].  The Food and Drug Adminstration Total Diet Study showed that PCB levels in the 
diet in 1993 were significantly less than 1/1000th the levels detected in the mid 1970s [46].  
The estimated dietary intake of PCBs for an average adult was approximately 0.03 ug/kg/day 
in 1978 and declined to <0.001 ug/kg/day by 1991 [23].   
Repeated cross-sectional studies of PCB show an overall decline in levels over time 
across populations [17, 47], reflecting the impact of the ban on PCB usage [46], and hence, 
environmental exposure levels [17, 46, 47].  However, interpreting and assessing trend from 
these data can be challenging given the variable component congeners of total PCBs across 
study populations and the non-standardization of measurement techniques across studies.  In 
a Swedish study of breastfeeding women, where survey data have been collected using a 
fairly consistent method over time, there is evidence of an upswing in breastmilk PCBs levels 
in the 1960s followed by a downturn, with total PCB levels in 1997 30% of that in 1972 [47].  
Analysis of the data from the National Human Adipose Tissue Survey in the United States 
shows a steady downward trend in the population percentage of individuals with total 
adipose tissue PCB levels >3ppm, from a high of nearly 10% in 1977 to 0% in 1983 [19].  
Nevertheless, despite the reduction in PCB production and usage, exposure is ongoing due to 
bioaccumulation.   
 
1.1.3 Intra-individual changes in DDE/PCBs over time 
 Given the ubiquity and potential health effects of these organochlorines, 
understanding the dynamics of individual body burdens of DDE and PCBs would have 
important health implications.  Studies with serial organochlorine measures among 
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occupational cohorts [29, 30, 48, 49] and individuals poisoned by very high acute levels of 
PCBs [50, 51] have shown dramatic declines in levels over a period of decades.  However, 
long term (>2 year) studies of intra-individual changes in DDE and PCBs among the general 
population, who are mostly exposed to relatively low, ongoing environmental levels of these 
pollutants have been limited [52-60] (TABLE 1.1).  These studies range in size from 35 to 
approximately 1500 participants and were conducted in various populations at different time 
periods (from the 1970s to 2002).  Eight of the 10 outlined studies had a follow-up interval of 
approximately 2 to 10 years, with the longest study about 20 years in duration.  
Baseline organochlorine levels and changes in those levels varied widely across 
studies, depending on the region, study population, study time period, and type of 
organochlorine and method of assessment.  However, there was an overall decline in intra-
individual DDE and PCB levels across all studies.  In a series of three studies, conducted 
from 1973 to 1995, in different subsets of the same cohort of Great Lakes fisheaters (>24 
pounds of fish in past year) and their low or non-eating (<6 pounds fish in past year) 
counterparts, declining levels of serum PCBs were partly attributed to a reduction in fish 
consumption [58] as well as declining environmental levels in contaminated fish [54].  In 
studies in which both organochlorines were assessed, the decline was more striking for DDE 
than for PCBs, particularly when the exposure measures were taken 10 years [53] or 7 years 
[54] apart.  These differences, however, were less noticeable in studies with follow-up 
measures taken over a span of 2 to 5 years [55, 60].   
These prospective studies confirm the trend seen in serial cross-sectional surveys that 
show human tissue levels of DDE and PCBs have dropped across various study populations 
and time periods.  This reduction may partly be explained by the declining environmental 
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levels resulting from their respective bans.  However, as changes to an individual’s body 
burden is related to a balance of intake and excretion, other host and environmental factors, 
including changes in metabolism, diet, weight, lactation, and age, may also play a role in 
shifting these levels over time. 
 
1.1.4 Correlations between serial DDE/PCB measures 
Correlation studies are important with respect to exposure assessment and 
determination of how well a measure at one time point reflects that at another time.  A 
number of short-term (<2 years) studies report high Spearman correlations (rs>0.8), a 
measure that evaluates the relationship between rank ordered measures, for serum DDE 
and/or PCB measures taken on average 2 months apart [61], before and after an overnight 
fast [62, 63], and across trimesters of pregnancy and shortly afterwards [64].  Similar 
correlations were found between breast milk DDE samples taken at birth to 6 weeks 
(rs=0.89), birth to 3 months (0.87) and birth to 6 months (0.86) in an approximately 2 year 
study of 807 lactating mothers [65].  These respective correlations were lower for total PCBs 
(0.74, 0.68, and 0.59).  It should be noted that in the latter study, lactation is a unique route of 
elimination that is generally not found at other times.  Overall, these short term studies reveal 
higher correlations among measures taken closer in time to one another than those temporally 
remote.    
Of the 10 aforementioned longitudinal studies of 2 or more years, four evaluated 
correlations between past and present organochlorine values [52, 53, 55, 60] (TABLE 1.2).  
In general, correlations between measures were sizeable (>0.5) for both DDE and PCBs, 
particularly highly chlorinated PCBs.  In a 2006 study of Faroes Island children who had 
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various PCB congeners measured at ages 7 and 14, the Pearson correlations evaluating the 
linear relationship between the two measures, were mostly greater than 0.5 for highly 
chlorinated PCBs (PCB-118, 153, 156, 157 and 180) and less than 0.2 for less chlorinated 
PCBs (PCB-18, 28, and 44) [52].  Spearman correlations were higher for DDE than for total 
PCBs in two studies of breast cancer cases and controls with approximately 2 years of 
follow-up (0.9 for DDE and 0.8 for PCBs) [60] and 7 years duration (0.79 for DDE and 0.64 
for PCBs) [55].  However, these differences were less noticeable when the predominant 
PCB-153 congener was evaluated; DDE and PCB-153 correlations were respectively 0.92 
and 0.90 in a 10-year study of 39 males by Hagmar et al. [53] and 0.79 and 0.68 in the 7-year 
study by Hoyer et al. [55].  The latter study further showed that correlations between 
measures varied by PCB congener.   
Overall, these short-term studies (<2 years) reveal relatively high correlations, which 
weakened the further apart organochlorine measures were taken in time from one another.  
Studies of 2- to 10-year duration show moderate to high (0.5 to 0.9) correlations for DDE and 
PCBs—the latter, depending on the specific congener analyzed.  These correlations 
demonstrate that a measure at one time point may be reflective of those at another time point 
up to 10 years apart.   
 
1.1.5 Predictors of DDE and PCBs levels 
An important goal in studies of etiology is to optimize exposure assessment by 
capturing or predicting the appropriate exposure levels at the time of etiologic relevance, 
thereby, giving a more accurate picture of the possible associations between the exposure and 
disease risk.  Numerous studies have evaluated a host of constitutive, demographic, and 
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behavioral factors that may predict a single measure of DDE and PCBs, including age, year 
of birth, gender, ethnicity, dietary factors (e.g. fish consumption), smoking, alcohol use, 
parity, lactation, measures of weight and adiposity, and relative weight change.   
The majority of studies show a positive association between age and concentrations 
of both DDT/DDE and PCBs [57, 66-71].  The few studies that do not show a relationship, 
generally, had small sample sizes, a limited age range to allow detection of an age difference, 
or a low exposure population [61, 72-74].  The positive association may be a function of an 
age-dependent accumulation.  Age may also be a marker for cohort-related changes in 
exposure levels, with older individuals being exposed to higher levels in the past [69, 75, 76], 
as well as a marker for age-related shifts in weight and metabolism.    
 In the large (n~6000) National Health and Nutrition Examination Survey (NHANES) 
from 2001-2002, no significant gender differences in levels of p,p’-DDE was reported.  
However, males had higher mean levels of PCB-153 and PCB-180 than females [25].  In the 
same study, Mexican Americans had higher levels of p,p’-DDE and PCB-153 than Non-
Hispanic Blacks and non-Hispanic Whites.  Non-Hispanic Blacks have higher levels of DDE, 
but similar levels of PCB-153 than non-Hispanic Whites.  It is unknown whether these 
gender and racial differences are associated with pharmacokinetics or due to differences in 
fat content.  Furthermore, differences with respect to occupation or residence (i.e. near 
agricultural areas that formerly used DDT) may contribute to the observed ethnic differences 
in DDE levels [76].   
As previously mentioned, diet is a major source of exposure to DDE and PCBs, with 
fish consumption the primary source for adults [68, 77-79].  Dairy products have generally 
not been associated with serum or milk levels of DDT/DDE or total PCBs [69, 80-82].   
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Numerous studies report no association between serum DDE and total PCBs and 
smoking (or smoking intensity) [67, 71, 72, 77], or likewise, no to minimal positive 
associations with alcohol consumption [67, 77, 82-84].  
Lactational transfer is a major route of elimination of organochlorines, with many 
studies showing an inverse association between lactation duration and DDE and PCB levels 
[65, 66, 81, 85-89].  Unifying this idea of lactational transfer is the positive associations 
found between breastfeeding duration and serum organochlorines in breastfed children [83, 
90-92].  Studies that found no effect of lactation generally had few women who breastfed or 
breastfed for long periods (>6 months), or had predominantly older women (>40 years) [71, 
80, 93-96].  The effect of lactation may have diminished by this older age.  
Placental transfer of organochlorines from mother to fetus has also been documented 
by the detection and correlation of PCBs or pesticides in both maternal and umbilical cord 
blood, suggesting that organochlorine levels would decrease with parity [97-99].  However, 
the effect of parity is mostly secondary to the effect of lactation.  Positive associations with 
parity are found in studies in which a majority of participants lactated [65, 82, 100, 101], 
whereas no association are generally found in studies with few women breastfeeding [72, 75, 
80, 93, 95].  Overall, lactational transfer to the child is considered the major route of 
organochlorine excretion in women, as evidenced by the much lower organochlorine 
concentrations in cord blood compared to maternal blood and breastmilk, despite the high 
correlations between all three samples [91, 102, 103].   
Since fatty tissue is the site of organochlorine sequestration, weight loss or a loss of 
body fat is expected to release organochlorines from fat, thereby elevating serum 
concentrations [104, 105].  Conversely, weight gain will lead to dilution of organochlorines 
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into fat tissue, thereby decreasing serum concentrations.  Cross-sectional analyses of the 
effect of weight change, mostly weight change in the recent past (<2 years), on a single 
measure of organochlorine have shown either an inverse association [71, 82, 106-108] or no 
effect [69, 70, 84, 109, 110].   
Body mass index (BMI) as a measure of adiposity is not related to DDE [65, 66, 69, 
80, 96, 109, 111] or total PCBs [58, 65, 70, 72, 77, 80, 93, 109, 110, 112, 113] in numerous 
studies, some of which accounted for the effect of lactation or were conducted in young 
lactating women [65, 69, 80, 96, 109, 110, 112].  Other studies have found positive 
associations with DDE [68, 70, 71, 93, 106, 113-117] and negative associations with total 
PCBs [60, 66, 67, 69, 75, 84, 108, 117, 118], although these relationships have not always 
held [68, 75, 96, 106].  Furthermore, BMI associations with individual PCB congeners do not 
follow any obvious pattern [71, 94, 114].   
These inconsistent associations with body mass index across studies and across 
organochlorine compounds have been postulated to be an outgrowth of multiple factors, 
including differential metabolism between heavier and leaner individuals, passive dilution of 
organochlorines in adipose tissue, and timing of sampling relative to the temporal changes in 
environmental exposure levels [106, 119].  Alcock et al. further suggested that the exposure 
patterns over time are a result of these complex interactions with other cohort-related and 
age-dependent changes in breastfeeding patterns, and dietary intake and composition [120]—
relationships which are difficult to evaluate in cross-sectional analyses using a single 
measure of organochlorine.  Nevertheless, these studies provide us with some clues on 
potential predictors of DDE and PCBs.    
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1.1.6 Predictors of intra-individual change in DDE and PCB levels 
To date, six prospective studies [53-55, 57, 59, 60], with a follow-up period of 2 or 
more years, have assessed the effects of some of the aforementioned factors on intra-
individual change in DDE and PCB levels (TABLE 1.2).  Two studies found that a single 
measure of body mass index at study enrollment was positively correlated with DDE, but not 
PCB, half-life [59, 60].  Half-life of DDE in the lowest quartile of body mass index was 4 
years compared to 7 years for the highest quartile [59].  Another study showed body mass 
index to be minimally associated (Odds ratio (OR)=1.07, 95% confidence interval (CI)=1.01-
1.13) with an increase in total PCBs [57].  Body mass index may be associated with reduced 
metabolism by xenobiotic-metabolizing enzymes such as cytochrome p450 (CYP).  CYPs of 
the 1A, 2B, and 3A family are most likely involved in the metabolism of various PCB 
congeners [23, 33, 121], and obesity has been associated with decreased activity of CYP 3A4 
in several studies [122].   
An inverse association between relative changes in body mass index or weight and 
changes in DDE/PCBs has been demonstrated in two studies [53, 55].  Since serum 
organochlorines are expected to be in passive pharmacodynamic equilibrium with adipose 
reservoir, an increase in weight may lead to the dilution of serum organochlorine 
concentrations, thereby giving a negative association [123].    
Two studies which evaluated age at study entry, controlling for the effects of weight 
change or a single measure of body mass index, found no significant associations with 
changes in DDE or PCB levels [53, 57], which contrasts with previous studies showing a 
positive association between age and a single measure of organochlorine [67-69, 124].  It is 
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possible that age, per se, may not be related to metabolism and excretion of these 
organochlorines, independent of body mass index.   
A number of short-term (<2 year) studies provide convincing evidence for the 
elimination of organochlorines via lactational transfer [65, 85, 86, 88, 89, 91, 125].  These 
studies show a decline in organochlorine levels with progressive lactations.  Wolff et al., 
however, found no effect of lactation duration on change in DDE or PCBs over a median of 
25.4 months of observation [60].  This study had only 35.2% of participants with a history of 
breastfeeding, and of those, 88% breastfed for 6 months or less, which may have limited the 
investigators’ ability to see an effect.   
Only two studies assessed the change in fish consumption on change in 
organochlorine levels over the periods of 1991-2001 [53] and 1982-1989 [54].  Although 
both studies found an overall reduction in serum DDE and PCB levels, these declines were 
not associated with altered fish consumption.  The authors suggest that the declines in serum 
levels are more likely to be explained by the reduction in environment levels, following their 
respective bans, rather than fish consumption.   
In addition to the factors mentioned above, initial concentration has also been 
evaluated as a potential predictor of change in organchlorine levels.  Previous studies of 
occupational cohorts with measures taken prior to and years after their exposure had ceased, 
demonstrate faster elimination of PCBs with higher initial concentrations [29-31].  Similarly, 
in a study of 701 women environmentally exposed to PCBs (median 31 months of follow-
up), those whose PCBs had decreased were over 3 times more likely to have higher initial 
concentrations than those who had maintained their levels [57].  Several  possible 
explanations have been proposed for this phenomenon [30], including “continuing exposure, 
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preferential retention of more slowly metabolized congeners, recent non-equilibrated 
exposure and greater enzyme induction at higher doses” [28].  
In summary, there are few long-term studies that have prospectively assessed the 
intra-individual changes, correlations and/or predictors of change in DDE and PCBs in 
populations exposed to relatively low levels.  These studies show an overall decline in DDE 
and PCB levels across various populations and time periods.  And these intra-individual 
changes may be a function of a multitude of factors, including lactation duration [56, 65], 
body mass index at study enrollment [59, 60], weight change [53, 55], and initial 
concentration [57].  Correlations between temporal measures were generally moderate to 
large (0.5-0.9) for both DDE and total PCBs, particularly higher molecular weight PCBs.   
It is unknown whether the changes, correlations, and predictors of change seen in 
these studies would continue with longer durations between measurements.  Understanding 
the long-term intra-individual changes in these organochlorines and the factors that influence 
organochlorine body burden would help to improve DDE/PCB exposure assessment in 
etiologic studies, particularly studies in which a single organochlorine measure is used.  A 
single measure may provide an imprecise picture of the etiologically relevant exposure levels 
that initiate the onset of disease or health outcome, such as menopause.    
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1.2 NATURAL MENOPAUSE 
1.2.1 Definition and Epidemiology 
Natural menopause is the permanent cessation of menstruation resulting from loss of 
ovarian follicular activity.  In the United States, the median age at menopause ranges from 48 
to 52 years, based mostly on samples of Caucasian women [126-129].  The Study of 
Women’s Health Across the Nation (SWAN) has estimated median age at menopause for 
multiethnic samples of US women to be 51.4 years [130].  The distribution of age at 
menopause includes a Gaussian portion between ages 47-55 years, with an extended lower 
tail [131-133].   
Ovarian failure before age 40 is considered premature and occurs with a frequency of 
0.3% to 0.9% [134, 135], whereas by age 45, about 5 to 10% of women have experienced 
menopause [129, 136].  Possible etiologies for premature ovarian failure include genetic 
[137, 138] or immune system defects [139-143], as well as ovarian insults, such as radiation 
[144] or chemotherapy [145].   
Aside from the very early age at onset of ovarian senescence, diagnosis of premature 
ovarian failure is based on a minimum of two elevated measures of follicle stimulating 
hormone (FSH) taken one or more months apart.  Various cutpoints have been used to define 
elevated FSH, including >20 and >40 international units per liter (IU/L) [146, 147].  In 
contrast, natural menopause is conventionally defined as the cessation of menstrual periods 
for at least 12 consecutive months [148, 149], in the absence of known causes, including 
pregnancy or lactation, and medical interventions [144, 145, 150, 151].   
Menopause is characterized by the depletion of the pool of ovarian follicles with a 
shift in ovarian steroid and gonadotropin hormones to a relative low estrogen and high 
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gonadotropin state.  Early age at natural menopause may be a marker for damage to the 
follicular pool or disruption of the hormonal feedback during the menopausal transition 
period (i.e. peri-menopause), which is typified by irregular menstrual cycle lengths and flow 
pattern up to five years prior to menopause [152].  Early age at menopause may influence the 
risk for heart disease [153] and osteoporosis [154], whereas late age at menopause may 
increase the risk for breast [155] and endometrial cancers [156]. Therefore, determining the 
factors that affect the timing of natural menopause is of substantial interest.   
Approximately 6 million oocytes per ovary are present in-utero.  At birth, about 2 
million oocytes remain [157] and these steadily deplete as a result of atresia or entry into the 
growth pool [158].  At any given time, most follicles are “resting” or arrested at prophase I of 
meiosis.  Beginning before birth and continuing throughout reproductive life, some of these 
resting primordial follicles, under the influence of unknown factors, are recruited into an 
initial growth phase whereby they transition through morphologically distinct stages: the 
primordial, primary, secondary (preantral) and antral follicles, the latter of which contain a 
developing fluid-filled antral cavity [159].  At the preantral and antral stage, most follicles 
undergo atresia until puberty and the reproductive years are reached, whereupon a few are 
“rescued” or recruited into a gonadotropin-dependent growth phase defined by the ovarian 
cycle, and the corresponding, menstrual cycle (See Figure 1.3).   
The ovarian cycle is characterized by alternating follicular and luteal phases.  The 
follicular phase is dominated by the presence of a maturing follicle ready for ovulation and 
fertilization.  A complex of hormonal changes occurs with a gradual rise in estrogen (i.e. 
estradiol or E2) and a surge in the gonadotropins, follicle stimulating hormone (FSH) and 
luteinizing hormone (LH), resulting in ovulation (release of a mature follicle or ovum) 
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(FIGURE 1.3 and 1.4).  This ovulation is followed by the luteal phase, which is characterized 
by the development of the corpus luteum in preparation for pregnancy.  Should fertilization 
not occur, the endometrial lining of the uterus and its blood vessels degenerate, accompanied 
by a drop in LH, estrogen, and progesterone, thereby resulting in menstruation and the 
beginning of a new menstrual cycle.   
During the reproductive years, about 400 oocytes will undergo ovulation, and the rest 
will undergo atresia.  At menopause, there are virtually no remaining follicles [160], and the 
ovary stops producing estrogen, thereby disrupting the feedback mechanism that suppresses 
FSH and LH production.  FSH levels increase 10-20 fold, and LH increase approximately 3 
fold [161, 162] during menopause compared to the reproductive years (FIGURE 1.4 and 1.5).  
The characteristic changes in circulating hormonal levels during transition to menopause 
allow these ovarian hormones to be used in classifying menopausal status.  As previously 
mentioned, serum FSH can be used in classification, with cutpoints at 20 IU/L or 40 IU/L.  
Some studies show better prediction of menopause with the latter cutpoint [163, 164]. 
Ideally, FSH measurement should be timed to the menstrual cycle, as a rise in FSH may be 
indicative of either menopause or a spike during ovulation.  A ratio of FSH to LH greater 
than 1 or 1.5 has also been used to define postmenopausal status [151, 165], and may be a 
better discriminator than FSH alone, even among women using oral contraceptives [165-
167].  FSH levels rise faster and higher than LH during menopause (FIGURE 1.5), whereas 
during the reproductive years, LH levels overtake those of FSH (FIGURE 1.4).  In addition, 
estradiol (E2) (<60 picogram per millliter for premenopause and >100 pg/mL for 
postmenopause), in combination with FSH, has also been used to discriminate menopause 
status among pre-menopausal and oophorectomized women [168].   
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Ovarian failure is typified by the depletion of the prenatally-determined primordial 
pool of ovarian follicles [159] and changes to ovarian steroid (estrogen) and gonadotropin 
(FSH and LH) levels [169].  Theoretical models based on biologic data suggest that the rate 
of atresia in the resting pool of primordial follicles during reproductive life, rather than the 
number of oocytes one is born with, has a greater influence on hastening the age at 
menopause [170].  It is possible that harmful exposures during menopausal transition can 
increase the rate of atresia [171] and disturb follicular growth and the ovarian hormonal 
milieu [172, 173] to a point at which the relatively small remaining pool of follicles cannot 
sustain recovery.  Numerous studies showing a more consistent effect of current smoking, 
compared to former smoking, on the age at menopause [114, 172, 174] support the notion 
that menopausal transition may be particularly vulnerable to the effects of potential ovarian 
toxicants.  
 
1.2.2  Factors associated with the timing of menopause 
Smoking is the best documented factor consistently associated with early age at 
menopause.  Numerous studies show an earlier age at menopause (generally, 1-2 years) for 
smokers, particularly current smoker, compared to non-smokers [129, 130, 134, 172, 175].  
Former smokers have about the same risk as non-smokers [175-177], independent of duration 
of smoking [172].  The number of cigarettes currently smoked appears to be influential in 
some studies [172, 177] but not in others [129, 176, 178].  The inconstencies may reflect 
errors in estimates of quantity smoked, which have generally been based on self-reports of 
current rate of cigarette consumption [179].  
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There is evidence for a strong genetic component to the timing of menopause from 
twin studies [180, 181].  The effect of family history of early menopause was evaluated in a 
case-control study of 344 women with early menopause (< age 46) who were age-matched to 
women who were still menstruating or who had menopause after age 46.  Women with early 
menopause were 6 times more likely to report a family history of menopause before age 46 
compared to control women [182].  In another study of 1081 randomly sampled women, ages 
45-54, those with premature (<age 40) and early (<age 46) menopause (defined as >6 months 
of amenorrhea) were also more likely to report a family history of early menopause (OR=6.0, 
95%CI=3.4-10.7) as compared to those still menstruating or those who had menopause after 
age 46, after adjusting for age and smoking status [183].  
Other studies have examined the effect of a hysterectomy or unilateral oophorectomy 
on menopause using hormonal measures of menopausal status [150, 151].  In a longitudinal 
study of 275 women who had an ovary conserving hysterectomy and 259 who did not have a 
hysterectomy, menopause (defined as FSH>40 IU/L) occurred 3.7 years earlier (95%CI=1.5-
6) in the hysterectomy group [150].  Among those with a hysterectomy, the women (n=28) 
who had a unilateral oophorectomy reached menopause 4.4 years earlier (95%CI=0.6-7.6) 
than those who retained both ovaries.  Similarly, a cross-sectional study of 1716 women, 
ages 35-49, found an increased prevalence of FSH>20 IU/L among those having had a 
hysterectomy with removal of one ovary compared to those who had not had hysterectomies 
or oophorectomies (OR=2.4, 95%CI=1.3-4.6) [151].  
Parity, later age at menarche, irregular cycle length and oral contraceptive use have 
been postulated to delay menopause, based on the premise that they are associated with 
reduced ovulatory cycles, and hence, preservation of oocytes [175].  Nulliparous women 
  21 
have been reported to have earlier menopause as compared to parous women [130, 175, 184], 
and increasing parity has been associated with later age at menopause in some studies [185-
188].  These observed effects may be explained by the notion that women with an early 
menopause are likely to have a shorter fertile period compared with women who have a later 
menopause.  Therefore, the relationship between age at menopause and parity may not be 
causal.  On the other hand, studies evaluating oral contraceptive use, irregular menstrual 
cycles and age at menarche have yielded contradictory findings [127, 130, 175, 185, 189-
191].   
The association between body mass index and age at menopause has also been 
inconsistent, with cross-sectional studies reporting no effect [192], earlier [193] as well as 
later [177, 190, 193] menopause in relation to higher body mass index [177, 191, 194].  
However, the association between higher body mass index and later age at menopause may 
partly be confounded by smoking status, with smokers generally being thinner.  A 3-year 
prospective study enrolling 2014 menstruating women, ages 46-56 years, found no effect of 
body mass index on timing of menopause (defined as 12 months of amenorrhea), after 
stratifying on smoking status [178].  Another prospective study of over 66,000 nurses over a 
2 year period found a weak relationship with age at menopause across quintiles of relative 
weight that was confined only to smokers [134]. 
 The relationship between alcohol use and age at menopause has been equivocal.  A 
few studies [189, 190] show a higher prevalence of early menopause among drinkers versus 
non-drinkers—one of which found a dose-response relationship [190].  Other studies report 
no effect [175, 195].   
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More recently, organochlorine pollutants, such as DDE and PCBs have been 
speculated to affect the timing of menopause.  Few studies have investigated the role of these 
compounds on age at menopause, and their results have been inconsistent.  Given the 
importance of menopausal age on the risk of late stage diseases and the environmental 
ubiquity of these organochlorines, further investigations are warranted to clarify their 
relationship.    
 
1.2.3  DDE/PCBs and age at menopause 
Many organochlorines are considered to be endocrine disruptors, in that they interfere 
with the synthesis or action of hormones in organs of the endocrine system, including the 
ovary.  Little is known about the effect of PCBs and DDE on the timing of menopause.  
However, there are a number of postulated biological mechanisms for the influence of these 
chemicals.  DDE has been detected in human ovarian follicular fluid [196] and repeated 
exposure to p.p’-DDE has been shown to decrease estrogen levels in porcine granulosa cells 
[197].  Whether this might influence age at menopause is unknown.  p,p’-DDE also has anti-
androgenic properties [8].  The reported effects of androgens on ovarian follicles can vary, 
and according to recent studies, may depend on the developmental stage of the follicles [198-
200].  Androgens have been reported to enhance follicular atresia in immature rats [201, 202] 
and reduce the number of large follicles [203].  However, recent data in animals, including 
rhesus monkeys, show that androgens, such as testosterone, directly stimulates the 
proliferation and growth of preantral and small antral ovarian follicles during the early stages 
of folliculogenesis [200, 204, 205] in a dose-dependent fashion [198, 199, 206], and this 
stimulatory effect is abrogated by flutamide, an anti-androgen [199].  Menopause is linked to 
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the exhaustion of early primordial follicles [159], so if androgens increase the rate of their 
development, early menopause might ensue.  The anti-androgenic effects of p,p’-DDE could 
be hypothesized  to delay menopause. 
PCBs may lead to premature menopause via the binding and activation of aryl 
hydrocarbon receptor (AhR), the same mechanism through which smoke-related toxicants 
[207] and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) may exert their effects [208].  Ahr 
binding induces the estrogen-metabolizing enzyme, cytochrome P4501A1 [209], thereby 
increasing 2-hydroxyestrogen concentrations [210].  Increased concentrations of 2-
hydroxyestrogen have been correlated with decreased serum estrogen levels in women who 
smoke [211] 
Some PCBs (e.g. PCB-28, 105, 118, and 156) have AhR binding capabilities and 
hence dioxin-like toxicity, though to a lesser extent than dioxin [25, 212, 213].  Chronic low 
dose exposure to TCDD has been reported to hasten reproductive senescence in female rats 
via the induction of a dose-dependent loss of normal cyclicity and estradiol levels, without a 
depletion to follicular reserve [208, 214].  Evidence in humans is not clear; one 
epidemiologic study of TCDD showed an inverted U-shape dose response relationship 
between TCDD and risk of early menopause among women accidentally exposed to high 
levels of TCDD [215].   
There are currently only four studies that have investigated the role of DDE and/or 
PCBs on the timing of menopause (see TABLE 1.3).  A study of 219 naturally menopausal 
Hispanic women, ages 42-74, reported a mean age at menopause 5.6 years earlier (p<0.01) 
for women in the highest category of p,p’-DDT (>6 ppb) versus those below the limit of 
detection (referent category), but variable effect for the middle three categories [16].  These 
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results were based on sparse data in the exposure categories, as 67% of the samples were 
below the limit of detection.  Similarly, for p,p’-DDE, the authors found an earlier mean age 
at menopause (1.5 years) for those in the upper quintile of exposure compared to the lowest 
quintile.  However, there is no trend in the mean ages at menopause across the middle three 
categories of exposures and information on the use of hormone replacement therapy (HRT) is 
lacking.  Because there was no data on HRT use, women who had undergone natural 
menopause but were still menstruating because of HRT use, may have been misclassified as 
being pre-menopausal.  
Blanck et al. conducted a prospective study of 874 women, ages 24-60, who were 
orally exposed to PCBs and polybrominated biphenyls (PBB), and found no effect of 
Arochlor 1254 on the timing of menopause [216].  This study had a high proportion (55%) of 
women with levels below the limit of detection, possibly making it difficult to observe an 
association.   
In a population-based study of breast cancer cases (n=748) and controls (n= 659), 
ages 21-74, Cooper et al. found little evidence for an association between PCBs and age at 
menopause [15].  However, women with higher compared to the lowest category of plasma 
DDE had monotonically higher rates of natural menopause, with those in the highest 10th 
percentile of DDE having a hazard ratio=1.4, 95% CI=0.9-2.1.  In this study, a sizeable 
proportion (25%) of women who were post-menopausal had their organochlorines measured 
20 years after the self-reported age at menopause, and current measures of serum 
organochlorines may not reflect past exposures.   In addition, 25 women with unknown 
menopausal status or who were taking hormone replacement therapy were excluded from 
analysis.  These excluded women may be experiencing menopause, and if their exposure 
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potential differs from those of the study participants, then biased estimates can result.  Lastly, 
those who reported natural menopause within a year of the interview were classified as pre-
menopausal, because it was uncertain whether these women truly were undergoing 
menopause.  If the last menstrual period (LMP) was actually the onset of menopause and 
censoring occurred at the interview (instead of at the LMP), this could lead to 
misclassification of menopausal status and mismeasurement of age at menopause.   
Analysis of a cohort of Taiwanese (Yucheng) women, ages 30-59, accidentally 
poisoned by high levels of PCBs revealed no difference in the menopausal status or mean age 
at menopause between women who were exposed and their neighborhood controls [217].  
This study was descriptive in nature and did not account for other covariates, and was 
furthermore, unique in terms of its study population being exposed to very high, acute levels.     
The evidence for an effect of DDE and PCBs remains unclear due to the 
inconsistencies in results, which may have stemmed from differences in study population and 
analytical strategies, including classification of menopause, criteria for exclusion/inclusion, 
and control for potential confounders.  One common thread between all of these studies is 
that organochlorines were measured in women at various ages (from 21-74 years), and for 
some studies in a large proportion of women who had already undergone menopause.  Given 
that women at different ages have different amounts of time to bioaccumulate 
organochlorines, the measures at different ages are not comparable between persons.  This 
incomparability is further complicated by the temporal changes in exposure levels over time 
as a result of cohort- and age-related shifts in environmental contamination, diet, metabolism, 
lactation, and weight.  The authors have attempted to account for the differences in age by 
controlling for age at enrollment in the model.  Nevertheless, exposures after the onset of 
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disease (or health outcome) are not the exposures of etiologic relevance.  Studies on smoking 
and age at menopause provide us with clues to possible reference periods.  Because current 
smoking has been consistently associated with the timing of menopause, the menopausal 
transition period is a likely time period that is sensitive to the effects of ovarian toxicants.  
Therefore, it is important to standardize organochlorine levels to a common age that is 
etiologically relevant.    
  
1.3 DISCUSSION AND SIGNIFICANCE OF PROPOSED RESEARCH 
DDE and PCBs are ubiquitous environmental pollutants that have been implicated in 
various health outcomes; more recently, the timing of menopause.  The age at menopause can 
influence the risk for heart disease, osteoporosis, breast and endometrial cancers, and 
infertility.  Though there is biological plausibility for their effects, the few epidemiologic 
studies that have investigated the role of these organochlorines on age at menopause have 
found inconsistent results.  While differences and inadequacies in analytical methodologies 
across studies may partly account for these results, exposure assessment using a single 
measure at widely divergent ages, temporally remote from the period of etiologic relevance, 
was a shortcoming in all studies.   
Efforts to estimate and standardize exposure measures to an age purported to be of 
etiologic significance have been limited by the lack of data on the changes and predictors of 
change in intra-individual body burdens of DDE and PCBs over the course of decades.  The 
few long-term studies that have prospectively assessed the intra-individual changes and 
predictors of change in DDE and PCBs, in populations exposed to relatively low levels, were 
2 to 10 years in duration and had variable or limited data on predictors and covariates.   
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Two previous studies have attempted to estimate past DDE and PCB levels using 
kinetic models that took into account current organochlorine values, the effect of lactation, 
and  decreasing concentrations in the environment (i.e. fatty fish) [6, 218].  Rylander et al. 
modeled PCB-153 levels in the past (1973-1991) based on current (1995) values and found a 
higher agreement between predicted and actual past levels as compared to current and actual 
past levels (kappa statistic (κ) of 0.52 versus 0.30, respectively) [218].  In a follow-up study 
with similar back-calculations for PCB-153 and DDE, Axmon et al. found a relatively small 
median difference (40 ng/g lipid) between estimated and actual past (1991) levels for both 
PCB-153 and DDE.  Lactation was found to have a major impact on estimation of past 
exposure [6].   
To address some of the limitations in previous studies, the following research was 
conducted, based on a prospective analysis in a relatively large cohort over a long period of 
time using questionnaire data and serum measures taken at baseline enrollment (1978-1982) 
and at follow-up (2003-2004) among female participants in the North Carolina Infant 
Feeding Study.  Serum organochlorines measures at baseline and follow-up will be used to 
characterize the intra-individual changes in DDE and PCBs over the ~25 year time period, in 
order to provide a model for exposure estimation.  In addition, serum gonadotropin and 
ovarian hormones data were used to augment classification of menopausal status and define 
the age at menopause.  A goal of this research is to enhance our understanding of the long-
term intra-individual dynamics of these organochlorine compounds, so as to improve 
exposure assessment in etiologic studies.  Another goal is to determine the effect on age at 
menopause of DDE and PCBs, estimated at an age posited to be of etiologic significance; 
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thereby contributing to our current knowledge of the public health significance of these 
organochlorines.  
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FIGURE 1.1 Chemical structures of DDT and DDE [2] 
 
 
 
 
 
 
 
 
FIGURE 1.2 Chemical structures of PCBs and a specific coplanar PCB [2] 
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Table 1.1  Prospective studies with serial DDE/PCB measures: Intra-individual changes  
Author, 
Yr, 
Location 
 
 
Population 
 
Study purpose 
to assess 
 
DDE/PCBs 
measured 
 
Sample period / 
follow-up time 
 
 
Levels at baseline 
 
Intra individual changes / 
Temporal trend 
Barr,  
2006,  
Faroes 
Island 
[52] 
 
1022 children PCB 
concentrations 
in a birth cohort 
Total and 
specific PCBs 
(ng/g lipid) 
At delivery, age 7  
and age 14 for PCBs 
(sample sizes differ at 
age 7 and 14)  
 
Median total PCB levels 
at age 7 
• 799 ng/g 
• At age 14, median total PCBs 
were 83% of their levels at 
age 7 
Hagmar,  
2006, 
Sweden  
[53] 
39 males intra-individual 
changes in DDE 
and PCBs 
serum DDE 
and PCB-153 
(ng/g lipid) 
1991 and 2001          Median levels in 1991 
• PCB = 340 ng/g 
• DDE = 650   
Median 1991 levels of  
• DDE were 31% of baseline  
• PCB-153 were 50% of 
baseline  
 
Hovinga, 
1992, 
Michigan 
[54] 
191 fisheaters 
and non-eaters 
(as designated 
in 1982 survey) 
historical 
changes in 
PCBs and DDT 
(comprised 
mostly of DDE) 
total serum 
DDT and 
PCBs (ppb) 
1982 and 1989          In fisheaters, mean 1982 
levels  
• DDT = 25.8 ppb 
• PCBs = 20.5  
In controls, mean 1982 
levels  
• DDT = 9.6 ppb 
• PCBs = 6.6  
In fisheaters, median 1989 
levels of 
• DDT were 60% of baseline  
• PCB were 43% of baseline  
In controls, median 1989 levels 
of  
• DDT were 71% of baseline  
• PCB were 103% of baseline  
 
Hoyer,  
2000, 
Denmark 
[55] 
 
429 breast 
cancer cases 
and controls 
risk of breast 
cancer and 
organochlorines 
blood DDE, 
total and 
congener 
specific PCB-
118, 138, 
153, and 180 
(ng/g lipid) 
1976-78 and 1981-83     Median levels in 1976-8 
• p,p’-DDE = 1197 ng/g 
• total PCBs = 1102  
• PCB-118 = 64  
• PCB-138 = 176  
• PCB-153 = 223  
• PCB-180 = 86   
Median 1981-3 levels of  
• DDE were 97% of baseline 
• Total PCBs were 89% of 
baseline 
• PCB-118 were 67% of 
baseline 
• PCB-138 were non-detectable 
• PCB-153 were 91% of 
baseline 
• PCB-180  were 95% of 
baseline 
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Table 1.1 (continue)   
Author, 
Yr, 
Location 
 
 
Population 
 
Study purpose 
to assess 
 
DDE/PCBs 
measured 
 
Sample period / 
follow-up time 
 
 
Levels at baseline 
 
Intra individual changes / 
Temporal trend 
Sasamoto, 
2006,  
Japan 
[56] 
35 women concentration of 
dioxin 
analogues in 
breast milk 
samples over 
time 
 
breastmilk 
dioxin-like 
PCBs (TEQ 
pg/g fat) 
1999-2000 and  
2001-02  
Average TEQ pg/g fat in 
1999/00 
• PCBs = 11 pg/g 
 
• Average TEQ pg/g fat in 
2001/2 were 60% of their 
TEQ in 1999/00 
 
Sweeney, 
2001, 
Michigan 
[57] 
701 accidentally 
exposed to PBB 
and PCB sealant 
predictors of 
change in PBB 
and  PCB levels 
serum total 
PCBs  (ppb) 
from 1975 to 1994 
(median time 
between sampling is 
31 months, range 1-
146 months)  
Median range of PCBs at 
enrollment, across age 
categories 
• 5-6 ppb 
 
• 37.5% of participants 
maintained their levels 
• 12.2% increased their levels 
by a median of 2ppb 
• 50.3% decreased their levels 
by a median of 3.0ppb 
 
Tee,  
2003, 
Michigan 
[58] 
179 fisheaters 
and noneaters 
(as defined in  
1980/2 survey) 
factors related 
to change in 
levels 
serum total 
PCBs (ppb) 
1980-82 and 1989-91 
and 1993-95 
(participants donated 
blood to at least 2 of 
3 surveys)       
Mean levels in survey 
periods 
• (1980-2) = 23 ppb 
• (1989-91) = 19  
• (1993-5) = 14  
• Median PCBs at 1989-91 
survey were 82% of baseline  
• Median PCBs at 1993-5 
survey were 61% of baseline 
• Authors suggest decline is due 
to a decrease in fish 
consumption  
 
Wolff,  
1999, 
Michigan 
[59] 
302 farm 
residents 
accidentally 
exposed to PBB 
and followed up  
sources & 
disposition of 
PBB with 
secondary 
analysis of DDE 
 
serum and 
adipose DDE 
(ppb) 
1976 and 1980      
 
Geometric mean DDE in 
1976 
• (males) = 3900 ppb 
• (females) = 3200  
 
Geometric mean 1980 levels 
were  
• 62% of baseline in males 
• 83% of baseline in females 
• Average half-life for adipose 
DDE ~6 years 
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  Table 1.1 (continue)   
Author, 
Yr, 
Location 
 
 
Population 
 
Study purpose 
to assess 
 
DDE/PCBs 
measured 
 
Sample period / 
follow-up time 
 
 
Levels at baseline 
 
Intra individual changes / 
Temporal trend 
Wolff,  
2000,  
New 
York 
[60] 
280 breast 
cancer cases 
and controls 
risk of breast 
cancer and 
organochlorines 
blood DDE 
and PCBs 
(ng/mL) 
1985-86 to 1987-90 
(>2 blood donations;  
median (range) of 
25.4 (5.8-70.6) 
months between 1st 
and last blood  
 
Geometric mean at 1st 
visit 
• DDE = 5 ng/mL 
• PCBs = 7.2  
 
Geometric mean at last visit for  
• DDE was 89% of baseline  
• PCBs was 94% of baseline  
• Median half life among 
controls for DDE (8.6 years) 
and PCB (11.2 years) 
 PBB=polybrominated biphenyls, TEQ = toxic equivalence factor 
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TABLE 1.2  Prospective studies with serial DDE/PCB measures: Correlations and predictors of change  
Author, 
Yr, 
Location 
 
 
Population 
 
DDE/PCBs 
measured 
Sample period 
/ follow-up 
time 
 
Correlation between 
measures at 
 
Predictors/control 
variables 
 
Potential predictors of 
change in DDE/PCBs  
Barr  
2006 
(Faroes 
Island) 
[52] 
 
1022 
children 
Total and 
specific 
PCBs (ng/g 
lipid) 
Age 7 and 14  Ages 7 and 14 
• High chlorinated PCBs 
(mostly rp>0.5) 
• Low chlorinates PCBs 
(mostly rp <0.2) 
 
  
Hagmar 
2006 
(Sweden) 
[53] 
39 males serum DDE 
and PCB-
153 (ng/g 
lipid) 
1991 and 2001         Year 2001 and 2001 
•  DDE (rs =0.92)      
•  PCB-153 (rs =0.90) 
• Age 
• Relative BMI change 
• 1991 fish 
consumption 
• Relative change in 
fish consumption 
from 1991-2000 
• fatty acid 
composition 
 
• Age was not related to a 
change in DDE or PCB-153 
• Relative increase in BMI 
weakly associated with 
decrease in DDE (β=-1.0, 
95% CI=-2.3, 0.2) 
• Relative increase in BMI 
associated with decrease in 
PCB-153 (β=-1.0, 95%CI=-
1.8, -0.2) 
• Change in DDE and PCB-
153 not related to age, fish 
consumption in 1991, 
relative change in fish 
consumption, or fatty acid 
composition 
 
Hovinga 
1992 
(Michigan) 
[54] 
191 
fisheaters 
and non-
eaters (as 
designated in 
1982 survey) 
 
total serum 
DDT and 
PCBs (ppb) 
1982 and 1989         • Age (-matched) 
• Fish consumption  
• Gender 
• Baseline 1982 serum 
levels  
 
• Fish consumption not 
associated with change in 
DDT and PCB 
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TABLE 1.2 (continue) 
Author, 
Yr, 
Location 
 
 
Population 
 
DDE/PCBs 
measured 
Sample period 
/ follow-up 
time 
 
Correlation between 
measures at 
 
Predictors/control 
variables 
 
Potential predictors of 
change in DDE/PCBs  
Hoyer 
2000 
(Denmark) 
[55] 
429 breast 
cancer cases 
and controls 
blood DDE, 
total and 
congener 
specific 
PCB-118, 
138, 153, 
and 180 
(ng/g lipid) 
1976-78 and 
1981-83      
Year 1976-78 and  
1981-83 
•  DDE (rs =0.79)   
•  PCBs (rs =0.64)       
•  PCB-118 (rs =0.32) 
•  PCB-138 (rs =0.57)       
•  PCB-153 (rs =0.68)    
•  PCB-180 (rs =0.54) 
 
• Weight loss/gain • Those who lost weight had a 
drop in their DDE and total 
PCB levels significantly less 
than expected    
• Those who gained weight 
had a significantly greater 
than expected drop in their 
PCB levels only.     
Sweeney 
2001 
(Michigan) 
[57] 
701 
accidentally 
exposed to 
PCB sealant 
serum total 
PCBs  (ppb) 
from 1975 to 
1994 (median 
time between 
sampling of 31 
months, range 
1-146 months)  
 • Age at enrollment 
• BMI at enrollment 
• Initial concentration 
• Having pregnancy 
between tests 
• Interval between 1st 
and last blood draw 
 
 
• Age at exposure (i.e. age at 
study entry) not significantly 
associated change in PCBs 
• High BMI associated with a 
minimal increase in PCBs 
(1.07, 95%CI=1.01-1.13), 
but borderline associated 
with a decrease in PCBs 
(0.94, 95%CI=0.88-1.0) 
• High initial PCB minimally 
associated with an increase 
in PCB (1.34, 95%CI=1.17-
1.53) but more strongly 
associated with a decrease 
(>-1 ppb) in PCBs  (3.26, 
95%CI=2.58-4.12)  
• Having a pregnancy and the 
interval between blood 
draws not associated with 
PCB change 
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TABLE 1.2 (continue) 
Author, 
Yr, 
Location 
 
 
Population 
 
DDE/PCBs 
measured 
Sample period 
/ follow-up 
time 
 
Correlation between 
measures at 
 
Predictors/control 
variables 
 
Potential predictors of 
change in DDE/PCBs  
Wolff  
1999 
(Michigan) 
[59] 
302 farm 
residents 
accidentally 
exposed to 
PBB and 
followed up 
later 
serum and 
adipose 
DDE (ppb) 
1976 and 1980     
 
 • BMI • A single BMI measure in 
1976 associated with DDE 
half-life  
• Half-life of adipose DDE in 
lowest quartile of BMI was 
4 yr compared with 7 years 
for highest quartile of BMI 
 
Wolff  
2000 
(New 
York) 
[60] 
280 breast 
cancer cases 
and controls 
blood DDE 
and PCBs 
(ng/mL) 
1985-86 to 
1987-90 (>2 
blood donations;  
median (range) 
of 25.4 (5.8-
70.6) months 
between 1st and 
last blood  
 
Visit 1 and 2: 
•  DDE (rs =0.93)   
•  PCB (rs =0.81) 
 
Visit 1 and 3:   
•  DDE (rs =0.95)   
•  PCB (rs =0.83) 
• BMI 
• Ever lactated 
 
• BMI positively correlated 
with DDE (rs=0.26, 
p<0.02), but not PCB, half-
life  
• No effect of lactation 
duration on half-lives  
  PBB=polybrominated biphenyls,  rp = Pearson correlation ,  rs = Spearman correlation  
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FIGURE 1.3  Correlation  between hormonal levels and cyclical ovarian and uterine 
changes [219] 
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FIGURE 1.4  Hormone levels during the menstrual cycle [220] 
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FIGURE 1.5  Hormone levels during menopausal transition and menopause [169] 
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TABLE 1.3  Studies of DDE and/or PCBs and age at menopause 
Author, 
Yr, 
Location 
 
 
Population 
Organochlorine 
exposure 
(median, range) 
Definition of natural 
menopause / Censoring / 
Exclusion 
 
 
Controlled for   
 
 
Results 
Akkina,  
2004,  
Colorado 
[16] 
219 
Hispanic 
women from 
HHANES, 
ages 42-74 
• p,p’-DDT (3.5 ppb) 
Categorized as <2, 2-
2.9, 3-3.9, 4-5.9, >6)  
(67% below LOD=2 
ppb) 
 
• p,p’-DDE (28.6 ppb) 
Categorized as <5.4, 
5.5-10.3, 10.4-16.0, 
16.1-23.5, >24.6 
 
 
 
 
• Excluded women with 
menopause of less than 35 
years  
• No info on HRT use   
 
• Age at exam  
• Hispanic group 
• Marital status 
• Family income  
• Education 
• Ever smoked 
• Alcohol 
• Residence 
• Born in US 
• Farm work 
• OC use  
• Age at menarche 
• Mean age at menopause 
across categories of p,p’-
DDT:  48.8, 47.7, 48.5, 46.7, 
43.2    
(p-value for difference b/w 1st 
and 3rd category was <0.01)   
 
• Mean age at menopause 
across quintiles of p,p-DDE:  
48.2, 48.8, 49.4, 48.0, 46.5    
(all with p-values >0.1) 
 
Blanck, 
2004, 
Michigan 
[216] 
990 women 
accidentally  
exposed to 
PBB, ages 
24-60 
• Arochlor 1254 
Categorized as <5pbb, 
>5-11ppb, >11ppb) 
(55% below 
LOD=5ppb) 
 
 
• 12 months amenorrhea 
(37%) 
• Censor at LMP is post-
menopause, start of HRT if 
use HRT (pre- and post-; 
sens anal), age at surgery if 
surgical menopause, current 
age if otherwise pre-
menopausal 
 
• Age at time of PBB 
exposure 
• Smoking (time-
varying) 
• BMI 
• Full-term 
pregnancies 
• Age at menarche 
• Ever use of OC 
• Household income  
• Education 
 
• No effect of Arochlor 1254 
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TABLE 1.3 (continue) 
Author, 
Yr, 
Location 
 
 
Population 
Organochlorine 
exposure 
(median, range) 
Definition of natural 
menopause / Censoring / 
Exclusion 
 
 
Controlled for   
 
 
Results 
Cooper, 
2002, 
North 
Carolina 
[15] 
1435 breast 
cancer cases 
and controls, 
ages 21-74 
• p,p’-DDE  
(3.1, 0.04-93.8 ng/mL; 
0.6 ug/g lipid) 
 
• Total PCBs  
(1.8, 0.3-26.1 ng/mL; 
0.4 ug/g lipid) 
 
 
• 12 months amenorrhea  
• Censored at LMP if 
postmenopause, age at 
surgery if surgical 
menopause, age at last menses 
if other medical reasons, at 
interview if otherwise pre-
menopause, 
• Those who reported natural 
menopause within a 1 yr of 
interview classified as pre-
menopause  
• Excluded women with 
unknown hormone status or 
missing data (n=59)  
• Samples collected after 
menopause (in 25% post-
menopausal, this was >20 
years after reported age at 
menopause)  
 
• Age at interview 
• Smoking (ages 18-
34 and 35-44) 
• Race (selection 
factor) 
• Education 
• Parity 
• Lactation 
• Physical activity 
• Thyroid condition 
• Body mass index 
 
• Monotonic increase in HR 
(95%CI) across percentile 
categories of  DDE (<50th, 
50th-74th, 75th-89th, >90th):  
1.0, 1.02 (0.9-1.6), 1.2 (0.9-
1.8), 1.3 (0.9-2.1) 
• HR for continuous DDE: 1.4 
(1.0-1.3) 
• No effect of total PCBs 
Yu,  
2000, 
Taiwan 
[217] 
680 PCB-
poisoned 
women and 
age-matched 
controls, 
ages 30-59 
• Poisoned by 
contaminated 
cooking oil (based 
on signs and 
symptoms of 
illness) 
• Descriptive analysis only • Age(-matched) • No difference in mean age at 
menopause between PCB-
exposed women and their 
controls  
 
PBB=polybrominated biphenyls, LOD = limit of detection, HRT=hormone replacement therapy, OC=oral contraceptives, LMP=last menstrual 
period, HR=hazard ratio 
  
2. SPECIFIC AIMS 
 
SPECIFIC AIM #1:  To determine the intra-individual changes and correlations in DDE 
and total PCB levels over a median of 24.4 years (1978-1982 to 2003-2004) 
 
SPECIFIC AIM #2:  To develop a model for the prediction of change in DDE and total  
PCB levels to be used for estimating organochlorine levels at age 40 (i.e. around the time of 
menopausal transition)   
 
SPECIFIC AIM #3:  To determine whether elevated levels of DDE and PCBs affect the 
timing of menopause  
  
3. MATERIALS AND METHODS 
 
3.1  STUDY POPULATIONS 
3.1.1 Baseline North Carolina Infant Feeding Study, n=877 
The baseline North Carolina Infant Feeding Study was conducted in Greenville, 
Raleigh and Durham cities in North Carolina, on a non-random sample of 877 pregnant 
women, who had given birth between 1978 and 1982 [1].  Six mothers bore twins and 47 had 
two study pregnancies during the study time period.  For those with two study pregnancies, 
the first will be considered the “index” pregnancy for the purposes of this dissertation.   
  At or near delivery, mothers who enrolled in the study were administered a 
questionnaire that elicited information on age, race, education, pre-pregnancy weight and 
weight gain during the current pregnancy, medical and pregnancy history, smoking, alcohol 
use, and breastfeeding history for the previous pregnancies.  Maternal and cord bloods and 
breast milk samples were also collected at that time for measurement of DDE and PCBs.  
Follow-up visits at 6 weeks, and 3 and 6 months postpartum consisted of questionnaires, 
collecting data on lactation and weight, as well as another blood sample at 6 weeks post-
partum, and periodic milk samples for as long as the child was breastfed.  Of the 877 women, 
12 had no samples to be analyzed for organochlorines.  The median levels of DDE and total 
PCBs in maternal serum at the birth of the index child were 12.8 and 9.8 ug/L serum, 
respectively.  
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Mothers were mostly white (92%), well-educated (53% with a college education or 
greater and 41% self-identified as professionals), and had a median age of 27 years (range 16 
to 41).  Eighteen percent smoked and 40% drank alcohol at least once a week.  Median pre-
pregnancy weight was 125 pounds (range 88-220 pounds).  Sixty-two percent were 
primiparous.  Among multiparous women, 62% had breastfed prior to the index pregnancy.  
Most (88%=704/804) breastfed the index child to some extent: 10% of those 704 continued 
for less than a month, 8.1% continued a year or more, and the median duration of 
breastfeeding was 24 weeks.   
 
3.1.2 Follow-up North Carolina Menopause Study, n=512 
 In 2003-2004, a follow-up North Carolina Menopause Study of participants from the 
North Carolina Infant Feeding Study was conducted to assess the relationship between 
organochlorine levels and ovarian senescence.  Of the 877 participants at the baseline study, 
12 (1.4%) were not eligible because they had no tissue samples, and 139 (15.8%) were not 
traceable due to missing contact information (TABLE 3.1).  Of the remaining 726, 118 
(16.3%) could not be found and 96 (13.3%) were lost due to refusal, death or other reasons; 
thereby, leaving 512 (58.4%) of the baseline participants, including 4 who had twin 
pregnancies and 34 who had two study pregnancies.  TABLE 3.2 presents selected baseline 
characteristics of participants and non-participants.  Aside from non-participants being 
slightly younger (mean age of 26.6 years compared to 28.1 years for participants) and having 
a slightly higher proportion of women with less than a high school education and being of 
Black race, non-participants and participants were similar in other respects, particularly their 
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organochlorine levels.  The participants will constitute the study population for Study Aim 3: 
evaluating the effect of DDE and PCBs on timing of menopause.   
At follow-up, a telephone-based questionnaire was administered to collect data on 
age, menstrual cycle history and menopause, detailed reproductive and breastfeeding history, 
medical history, surgery and cancer treatment, use of hormone replacement therapy (HRT) 
and birth control hormones, smoking, alcohol use, and height and weight (TABLE 3.3).   
Blood was also drawn on subset of women, shortly thereafter, for two purposes: 1) 
measurement of DDE and PCBs and 2) measurement of the ovarian hormones: follicle 
stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2) (TABLE 3.4).  The 
selection probabilities for a blood draw were as follows: all women under age 55 whose 
menopausal status was unclear due to a hysterectomy with retention of >1 ovary (n=41), 
current use of hormone replacement therapy without having had a hysterectomy (n=39), and 
symptoms of peri-menopause (n=107), plus a 30% random sample of everyone else (n=98), 
regardless of age.  At the time of the blood draw, women were also asked the age and date of 
their last menstrual period.  Twenty-three (12.2%) of those with unclear menopausal status 
and 18 (18.4%) of the random others refused to donate blood, and an additional 2 (2%) 
samples from those randomly selected were lost in transit.   
Blood samples from 126 women (constituting 82% of a 30% random sample of the 
512 follow-up participants) were sent for DDE and PCB analysis.  These women will 
comprise the study population for Study Aims 1 and 2.    
A total of 203 blood samples collected from women with unclear menopausal status 
and half of the group of random others were sent for FSH, LH and E2 analysis.  Twenty-two 
random blood duplicates were also sent.   These ovarian hormones were used to augment the 
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classification of menopausal status among those whose status was unclear, for the purposes 
of Study Aim 3.  The coefficients of variations for FSH, LH, and E2 were 3.8%, 4.6%, and 
17.9%, respectively.  Classification of menopausal status did not change whether the original 
or duplicate sample was used.   
 
3.2  ORGANOCHLORINE MEASUREMENT 
3.2.1 DDE and PCBs in baseline study  
At baseline, p,p’-DDE and total PCBs were extracted with a mixture of 
hexane/ether/ethanol, purified with florisil, and assayed using packed column gas 
chromatography coupled with electron capture detection.  Total PCBs was quantitated as the 
sum of two peaks on a chromatogram [2].  The coefficients of variation were <12%.  
Organochlorine levels were recovery-adjusted to account for the less than 100% recovery of 
chemicals.  The limits of detection were variable and dependent on sample volume.  Serum 
measures were not lipid-adjusted (i.e. wet weight) because intra-individual variability in the 
lipid content was considered minimal compared to those in breast milk.  However, due to the 
high variability in milk fat content between women and over the course of lactation [3], milk 
samples were lipid-adjusted and expressed as ug/g lipid.   
 Among participants with DDE/PCB measurements, not all had each type of sample 
nor had detectable levels, and therefore, to maximize the data usage, values from all tissue 
(maternal serum, breast milk and cord blood) specimens were combined and expressed as an 
estimated “composite” measure of organochlorine in milk at birth [1].  First, any sample with 
a level below the limit of detection, was assigned an estimated value.  Assuming that 
organochlorines were log normally distributed, this imputed value was calculated by 
estimating the expected value conditional on being less than the quantitation limit [4].  To 
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allow for comparability to milk at birth, these levels were then multiplied by a scaling factor 
(median ratio of birth milk sample to the sample in question), which adjusted for the 
declining milk values over time and for the much lower levels in blood compared to milk.  
All available rescaled levels were then averaged. The correlation between the estimated and 
actual amount in available milk was 0.94 for DDE and 0.86 for PCBs [1].  These composite 
measures supplemented the measures that were directly available in serum and breast milk.   
 
3.2.2 DDE and PCBs in follow-up study 
At follow-up, serum measures of p,p’-DDE, congener-specific PCBs and total PCBs 
(as an aggregate of the 14 measured congeners: PCB-28, 52, 99, 101, 105, 118, 128, 138, 
153, 156, 170, 180, 183, and 187) were determined upon extraction using a mixture of 
ammonium sulfate/ethanol/hexane, purification with florisil, and quantitation using high 
resolution gas chromatography coupled with mass spectrometry (GC-MS).  The coefficients 
of variation were 5.1% for DDE and 3.5%-11.4% for the various PCB congeners.  The limit 
of detection was 0.2 for PCB-52, 0.03 for PCB-28, and 0.02 for the remaining PCB 
congeners and DDE.  Total lipids were also estimated from total cholesterol, phospholipids 
and triglycerides using the Phillips equation [5], thereby allowing concentrations to be 
expressed per gram of lipid.  A validation study shows that this approach [5] gives values 
very similar to those obtained using the standard gravimetric lipid analysis [6].  Hence, both 
wet weight and lipid-adjusted serum measures were available.  Comparison of wet weight to 
their corresponding lipid-adjusted DDE measures show Pearson and Spearman correlations 
greater than 0.97, thereby lending support to the aforementioned assumption that intra-
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individual lipid variability is minimal in serum as well as suggesting the feasibility of directly 
analyzing wet weight serum measures.    
 
3.3 METHODOLOGY FOR STUDY AIM 1 
The goals of Study Aims 1 were to evaluate the intra-individual changes and 
correlations between baseline and follow-up serum wet weight DDE and PCBs.  Of the 126 
women with a follow-up organochlorine measure (TABLE 3.4), 3 were missing baseline 
serum and were excluded from final analyses.   
The distributions, extent of missing values and non-detects in DDE and PCB 
measures at both baseline and follow-up were explored.  At follow-up, there was an 
appreciable amount of non-detectable levels (52%-98%) in 6 of the 14 PCB congeners (PCB-
28, 52, 101, 105, 128, and 183) (TABLE 3.5).  Given these congeners comprise a small 
proportion (<6%) of the sum of all 14 congeners, the remainder of this document will 
evaluate PCBs as the sum of the remaining 8 congeners (PCB-99, 118, 138, 153, 156, 170, 
180, and 187), which have the lowest proportion of non-detects (<18%) and the highest 
relative abundance (together comprising ~94% of the sum of all PCB congeners measured).   
 In comparing baseline to follow-up organochlorine measures, some issues need to be 
considered regarding how to deal with: 1) the changes in quantitation methods since the 
baseline study, 2) non-detects, and 3) pregnancy related increases in lipids and 
organochlorines.  TABLE 3.6 provides an overview of the following sections (3.3.1 -3.3.4) 
that address these issues.    
 
3.3.1 Accounting for the change in PCB quantitation methods 
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There was no appreciable change in the extraction method for either DDE or PCBs, 
and the recovery rates were very high for the follow-up study (>93% for DDE and >92% for 
PCBs).  Furthermore, DDE quantitation (which involves measurement of a single peak) was 
the same at baseline and follow-up.  However, the PCB quantitation methods used at baseline 
differed from those used at follow-up and do not produce directly comparable results. To 
convert baseline PCB concentrations into their follow-up equivalents, 10 baseline milk 
samples, spanning the range of PCB levels, were reanalyzed by the follow-up GC-MS 
methodology [7].  Baseline levels were multiplied by the median ratio (0.236127) of 
concentration using the follow-up method to concentration using the baseline method.  To 
evaluate the validity of this conversion, the observed milk PCB values obtained by the 
follow-up method was compared to those estimated by converting the baseline method to the 
follow-up method.  The Pearson and Spearman correlations between the observed and 
estimated levels were very high (0.96 and 0.83, respectively), indicating the feasibility of this 
conversion factor (FIGURE 3.1).   
 
3.3.2 Handling non-detects 
At baseline, 1 (1%) individual had non-detectable serum DDE and 18 (14.6%) had 
non-detectable serum PCBs.  Serum organochlorine concentrations below the limit of 
detection (LOD) at baseline were assigned estimated values using the aforementioned 
“composite” measures that reflect the concentration in milk lipids at birth of the index child 
[1].  These composite measures were converted into their approximate serum equivalent by 
multiplying by the median ratio of serum to composite concentrations (5.0071367 for DDE 
and 5.4120890 for PCBs) obtained from members of the baseline population with detectable 
serum values.  To evaluate the validity of this imputation, estimated and actual 
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concentrations among those with detectable levels in serum at delivery were compared.  The 
mean % difference and standard deviation were 6.1 + 36.9 for DDE and 3.8 + 24.3 for PCBs.  
Pearson and Spearman correlations were high between estimated and observed values for 
both DDE (0.90 and 0.91, respectively) and PCBs (0.91 and 0.84) (FIGURES 3.2 and 3.3).   
At follow-up, one individual had non-detectable serum DDE, whereas 28 (22.8%) had 
at least one non-detectable PCB congener among the 8 most abundant congeners considered.  
Non-detects at follow-up were assumed to have a log normal distribution and were assigned 
the limit of detection (LOD) divided by the square root of 2 [8].  To determine whether the 
method by which non-detects are imputed makes a difference, estimated total PCB values 
using LOD for non-detects, and alternatively, using 0 for non-detects were compared.  
Estimated values using our primary method (LOD/square root 2) for handling non-detects 
will fall between those obtained using LOD and 0.  The ratio of PCBs (i.e. sum of 8 
congeners) using LOD for non-detects to PCBs using 0 for non-detects show a greater than 
10% difference (range 12-156%) for only 6 individuals.  
 
3.3.3 Accounting for pregnancy-related increase in DDE and PCBs 
As serum lipids were not available at baseline, our primary goal was to explore 
changes in wet weight serum organochlorine measures over time. Measures at baseline were 
acquired at or around the time of delivery; however, short-term changes due to pregnancy are 
not the changes of interest.  Given the characteristic and consistent rise in lipid content across 
pregnancy [9-15] and the consequential elevation in organochlorines, wet weight serum 
measures were adjusted to reflect non-pregnant levels.  Based on mean serum total lipids of 
5.9 g/L among more than 2000 non-pregnant Caucasian women, aged 20-34, participating in 
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the 1976-80 National Health and Nutrition Examination Survey [16, 17] and 8.5 g/L in a 
1977-79 study of 553 pregnant Caucasian women, ages 20-41, at 36 weeks of gestation [14], 
a 30% increase in total lipids across pregnancy was estimated.  To account for this rise, wet 
weight serum concentrations at baseline were reduced by an equivalent amount (i.e. by 
multiplying by 0.7).   
 
3.3.4 Secondary analysis of lipid-adjusted serum measures  
Though the primary analysis was based on wet weight organochlorines, a secondary 
analysis was conducted on estimated lipid-adjusted measures.  Lipid-adjusted serum 
concentrations at baseline were estimated by dividing the aforementioned “composite” values 
by a correction factor (1.5) that accounts for the difference in lipid concentrations between 
milk and serum.  This factor is the approximate ratio of concentrations in milk lipids to those 
in serum lipids for both DDE [18, 19] and PCBs [19, 20].  
 
3.3.5  Statistical analysis 
Descriptive analyses of DDE and PCB measures, at both baseline and follow-up, 
were conducted, including means, medians, miminum and maximum values, and percentile 
distributions.  Separate analyses were done for wet weight and estimated lipid-adjusted 
measures.  The relative change in levels over the two study periods was evaluated as the ratio 
of follow-up to baseline concentrations.  Non-parametric Spearman correlation coefficients, 
which are not susceptible to influential observations, as well as graphical plots were used to 
assess the relationship between baseline and follow-up serum measures.   
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3.4 METHODOLOGY FOR STUDY AIM 2 
The goal of Study Aim 2 is to model the predictors of change in DDE and PCBs, so 
as to provide a model for exposure estimation at a time of etiologic relevance to menopause 
(i.e. Study Aim 3).  Of the 123 women with both baseline and follow-up organochlorine 
measures, one individual had missing pregnancy information and was excluded from this 
analysis.  
 
3.4.1  Predictive model 
Although changes in serum DDE and PCB levels over time are driven by complex 
age- and cohort-related processes, we presume the changes in organochlorine levels during 
the period under study could be reasonably approximated by an exponential decay, as other 
similar compounds and biological systems tend to operate on an exponential decay [21, 22]. 
Thus, the basic predictive model was:   
 
[Follow-up] = [Baseline] ∗ exp ( - slope ∗ follow-up time)    
 
which can be re-written as  
 
Log [Follow-up] – Log [Baseline]  = - slope   
follow-up time 
 
[Follow-up] and [Baseline] are the wet weight organochlorine concentrations, respectively, at 
follow-up and baseline, and “follow-up time” represents the years from baseline to follow-
up.  Slope represents change in log concentrations per unit of follow-up time.  To determine 
whether slope (i.e. the rate of change) is constant or is affected by various determinants, 
linear regression was used, such that the full model is of the form:  
  73 
 
Log [Follow-up] – Log [Baseline]  =  - (α + β1 (X1) . . . + βk (Xk)) 
follow-up time 
 
where α is the intercept and βk is the regression coefficient for the k-th predictor, Xk.   
 
3.4.2 Potential predictors 
Initial concentration, lactation duration, body mass index at baseline, percent change 
in fat mass, and mother’s date of birth were evaluated for their possible influence on the rate 
of change in DDE and PCBs from the baseline to the follow-up study.  Univariate statistics, 
including frequencies, means and medians were generated for these variables.   The 
distributions of each of the variables were examined to check for missing data.  One 
individual with missing pregnancy information was dropped from analysis.  Missing 
observations for weight at baseline (n=3) and at follow-up (n=5) were derived or imputed 
from other available data.  For missing baseline weight, the reported weight at the 6 week 
and 6 month interviews following the index pregnancy was used.  For missing follow-up 
weight, categories of weight were available at the follow-up interview and the midpoint of 
each category was taken as the weight).  Two individuals were missing age at menarche.  
One reported her first period in 5th grade and was assigned 11 as her age at menarche.  
Various coding schemes (continuous and categorical) were explored.  Each potential 
predictor was examined to obtain the fewest categories needed to adequately characterize the 
relationship between that variable and the slope.   
 Initial (baseline) DDE and PCB concentrations (ug/L serum) were log-transformed, 
given their log normal distributions, and were included in the model as a linear variable.   
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Lactation duration, as assessed from the follow-up questionnaire, was defined as the 
number of weeks the participant breast-fed twice or more per day.  Given the diminishing 
role of exclusive breast-feeding as lactation proceeds, the effect of breast-feeding on the rate 
of organochlorine excretion could lessen later in lactation.  Thus, lactation duration was 
treated as a continuous variable and fitted with a piecewise linear model over 3 intervals of 
lactation duration, with the slope of each interval estimated directly from the data.  This was 
accomplished by defining 3 variables representing the number of weeks of lactation during 
the 3 intervals: 0-26th, 27th-39th, and >39th lactational week.  The number of weeks of breast-
feeding for each pregnancy from baseline to follow-up was split among these three variables.  
Additional cutpoints at the quarter (13 weeks) and the 1 year (52 weeks) time points did not 
change the results.  The number of weeks of breast-feeding for each pregnancy from baseline 
to follow-up was split among these three variables.  For women with multiple lactations 
between baseline and follow-up, the contribution from each pregnancy was summed.  To 
illustrate, for a woman with one child whose lactation lasted 60 weeks, a value of 26, 13 and 
21 weeks was assigned to the first, second and third lactation variables, respectively.  If she 
also had a second child who was breastfed for 30 weeks, then an additional 26 weeks was 
assigned to the first lactation variable and 4 weeks to the second, giving final values of 52, 
17, and 21 for the three lactation variables.  To operationalize in modeling, the value (i.e. 
number of breastfeeding weeks) of each of the three variables would be multiplied by the 
beta coefficients obtained for the corresponding variable.   
Baseline body mass index was included in the model as a categorical predictor.  Due 
to its narrow distribution, cutpoints for body mass index were set at 20 and 23 kg/m2. 
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Percent change in body fat (kg) was based on a validated formula for percent body 
fat, which was then converted to body fat by multiplying by body weight [23]:   
 
Body fat = [((1.46∗BMI) + (0.14∗age) – 10) / 100] ∗ weight 
 
Usual weight prior to baseline study pregnancy and current weight were obtained, 
respectively, from the baseline and follow-up questionnaires.  Percentage change in body fat, 
defined as the difference in body fat from baseline to follow-up divided by baseline body fat, 
was included as a linear variable.   
Mother’s date of birth, a marker of secular trend in environmental DDE/PCB levels, 
was included as a continuous variable with unit in days (i.e. as a SAS date with reference 
date of January 1, 1960).  Though baseline maternal age was another potential predictor, it 
was not included because it was highly correlated with date of birth (r=0.97). 
 
3.4.3  Statistical analysis 
 For predictive modeling, linear regression models were fit using SAS (version 9.1).  
The statistical significance of each variable was assessed using the F test.  Spearman 
correlations comparing actual versus model-predicted concentrations at follow-up were used 
to assess the predictiveness of each model.  To illustrate the model fits, model-predicted 
changes in organochlorine levels were plotted along with actual changes for the 122 
individuals with non-missing questionnaire data.     
 
3.5 METHODOLOGY FOR STUDY AIM 3 
The goal of Study Aim 3 is to determine whether the timing of menopause is 
influenced by DDE and PCB levels, estimated at a common age that is likely to be of 
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etiologic significance.   For the 512 participants in the North Carolina Menopause Study, 
serum DDE and PCB levels were estimated at age 40, around the time of menopausal 
transition, using the regression coefficients from the predictive model in Study Aim 2.   
 
3.5.1 Exposure: DDE and PCBs at age 40 
Predicted levels at age 40 were obtained using the following equation:  
[FU] = [BS] * exp [-(a + β1 (init conc) + β2 (lact1) + β3 (lact2) + β4 (lact3) + β5 (bBMI1) + 
β6 (bBMI2) + β7(fat change)) * time] 
 
where  
[FU] = serum organochlorine concentration at age 40 (ug/L) 
[BS] = baseline organochlorine serum concentration (ug/L) 
init conc = log of initial (baseline) serum concentration (ug/L) 
lact1 = number of weeks of breastfeeding during the 0-26 weeks lactation period for every 
child born from the baseline study until the mother reaches age 40 
 
lact2 = number of weeks of breastfeeding during the 27-39 weeks lactation period . . . 
lact3 = number of weeks of breastfeeding during the >39 weeks lactation period . . . 
bBMI1 = having a body mass index at baseline of 20-22.9 kg/m2 
bBMI2 = having a body mass index at baseline of >23 kg/m2 
fat change = percent change in fat mass from baseline to age 40; via linear interpolation  
 of fat mass at baseline and follow-up 
 
time = time span from baseline to age 40 (yrs) 
α and β1 to β6 = regression coefficients obtained from the predictive model in Study  
 Aim 2 
 
Estimated organochlorine levels were evaluated as both continuous and categorical 
variables, with similar results.  Categories were established using a natural cutpoint close to 
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the upper 10th percentile for the highest DDE and PCB category, and approximately evenly 
dividing the remaining concentrations into 4 additional ranges.  This produced a lowest 
referent category that was adequately large (>25%).    
 
3.5.2 Outcome:  Age at natural menopause  
Natural menopause is defined as having >12 months of amenorrhea, not due to 
surgery, pregnancy, lactation, radiation, chemotherapy, or known medical causes.  The onset 
of menopause is defined as the time of the final menstrual bleeding.  However, unless a 
bleeding free year has already passed, it is not possible to determine whether the last 
observed menstrual period is the final menstrual period.  Events, such as having a 
hysterectomy or the interview within 12 months of the last observed menstrual period will 
prevent one from seeing the future, and hence, the true age at menopause.  Given these 
events, individuals would be censored, such that their age at onset of menopause occurs on or 
after the censored time point.  
Censoring was conducted with the goal of correctly classifying menopausal status and 
measuring the age at menopause.  For example, assume the interview occurred 3 months after 
the last observed menstrual period (LMP).  Since a year of amenorrhea has yet to pass, we do 
not know if this menstrual period is actually the final menstrual period (FMP), defining the 
onset of menopause.  Censoring would occur at the LMP.  The same censoring strategy (i.e. 
censoring at LMP) would apply to women with an ovary-preserving hysterectomy or bilateral 
oophorectomy within 12 months following the LMP or for women with radiation or 
chemotherapy treatment within 12 months of the LMP.  For the one participant who was 
currently pregnant, censoring occurred at the time of the interview.   
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For 203 women (<55 years of age) with unclear menopausal status and a random 
sample of everyone else (TABLE  3.4), follicle stimulating hormone (FSH), luteinizing 
hormone (LH) and estradiol (E2) measures were available and used to confirm or augment 
classification of menopausal status and narrow the time window in which menopause is 
expected to occur.  Classification of menopause proceeded in a 3 step process whereby an 
individual was assigned a menopausal status based first on her level of FSH (pre-menopausal 
if FSH<15 and post-menopausal if FSH>40) (TABLE 3.7).  For women whose FSH fell 
within a range (15-40 IU/L) in which status could not be clearly defined, then E2 levels were 
used (premenopausal if E2>100 and post-menopausal if E2<60).  If the E2 levels fell within a 
range (60-100 pg/mL) that did not allow resolution of menopausal status, then the ratio of 
FSH/LH was used (premenopausal if FSH/LH<1 and postmenopausal if FSH/LH>1).  The 
cutpoints used for each step were selected to take into account the distribution and levels of 
all three ovarian hormones at different stages of reproductive life [24] as well as literature 
suggesting optimal cutpoints for FSH [25, 26], E2 [27] and FSH/LH ratio [28, 29].    
The supplementary hormone data allows refinement of the time window in which 
women’s onset of menopause occurs, which therefore increases precision.  For women who 
had radiation or chemotherapy within a year of the last menstrual period, censoring would 
still begin at the LMP, regardless of the hormone data (TABLE 3.8).  The hormone data is 
not reliable among these women given the varying effects of radiation and chemotherapy: 
women can either experience premature menopause or can eventually regain their menstrual 
cycles, and therefore, censoring at any time after the last menstrual period would be 
erroneous.  Likewise, those currently pregnant would be censored at the time of the interview 
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and those missing a date for the last menstrual period would be censored at the return of 
menses following the last pregnancy.  
If the hormone data indicates pre-menopausal status, then censoring would occur at 
the time of the follow-up blood draw, rather than at the last menstrual period.  If the hormone 
data suggests postmenopausal status, then censoring would begin at the last menstrual period 
for those with a bilateral oophorectomy, whereas censoring would occur between the last 
menstrual period and follow-up blood draw (“interval censored”) for those with a 
hysterectomy but still retain >1 ovary.  For everyone else, natural menopause would occur at 
the last menstrual period. 
In a secondary analysis, assignment of menopause status and age took into account 
the effect of hormone replacement therapy (HRT) use.  Hormone replacement therapy can 
cause postmenopausal “breakthrough” bleeding, thereby masking the true onset of 
menopause [30].  Hence, if an episode of hormone replacement therapy began before the last 
menstrual period and lasted at least until one year prior to LMP, the following guidelines 
were used to define menopausal status: if FSH/LH/E2 data suggest she is pre-menopausal, 
censor at the blood draw, otherwise, extend the left side of the menopause interval, as defined 
by the rules outlined above, to include the whole HRT episode (if it does not already).  For a 
woman who reported using oral contraceptives for menopausal symptoms, her last episode of 
oral contraceptive was treated as hormone replacement therapy.  Multiple episodes of HRT 
use separated by a <1 year gap were treated as one continuous episode. 
Some methodologic considerations should be noted in using FSH, LH and E2 for 
classifying menopausal status.  Given that serum measures were not timed to the menstrual 
cycle, use of this FSH/LH/E2 algorithm would better discriminate menopausal status 
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compared to FSH alone.  However, for those taking hormone replacement therapy, it is still 
possible that menopausal status could be misclassified using this algorithm, given that 
introduction of exogenous estrogen can artificially decrease the FSH levels, thereby, causing 
some postmenopausal women to be classified something other than postmenopausal.  Among 
women with a bilateral oophorectomy participating in the National Health and Nutrition 
Examination Study (NHANES), the same proportion (~85%) of women taking HRT and 
women not taking HRT had elevated FSH levels defined as more than 20 IU/L.  In contrast, 
52% of those taking HRT and 67% of those not taking HRT had FSH levels above 40 [31].  
In North Carolina Menopause Study, 33 of 39 women who were currently taking hormone 
replacement therapy had hormone measures.  Of these, 25 had FSH>40 IU/L and were 
assumed to be correctly defined as postmenopausal, whereas 4 individuals had FSH<15 IU/L 
and were assumed to be correctly defined as premenopausal, given the findings in NHANES.  
Only the remaining 4 individuals had 15<FSH<40 (12% of those taking HRT), who may 
have been subject to misclassification of menopausal status.   
Among women with unclear menopausal status, ovarian hormone analysis was 
limited to those less than 55 years of age.  Excluding women age>55 should not bias the 
estimate of effect however, as menopausal status for any one individual is not misclassified.  
Rather, for those with unclear menopausal status, age 55 and over, the time window in which 
her menopausal experience is expected could not be refined (i.e. precision is not improved), 
because she did not have the benefit of the additional hormone information.  
The hormone algorithm in this study has not been validated.  However, there was 
high agreement between the interview and hormone data among those with clearly defined 
postmenopausal status (i.e. those with a bilateral oophorectomy and >1 year amenorrhea).  Of 
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the 54 women with >1 year of amenorrhea and hormone data, 53 were defined as 
postmenopausal by hormone.  Of the 10 with a bilateral oophorectomy and hormone data, 9 
were classified as postmenopausal by hormone.  For the one individual who reported having 
both ovaries removed but whose hormone data (FSH=22, LH=11.14 and estradiol=162.45) 
suggests she was currently premenopausal, the hormone data was taken to be correct.  A 
duplicate blood sample on this individual did not change her hormonal classification.  It is 
unclear whether the participant misreported the number of ovaries removed.   
 
3.5.3 Covariates  
 Factors that have been associated with age at menopause but are not on the causal 
pathway from exposure to outcome and which data were available were included in 
regression model.  Data on these variables were collected at the follow-up study, except for 
BMI at age 40, which was estimated based on the change in BMI from the baseline to follow-
up interview.   
Information on cigarette smoking was used to construct a dichotomous indicator 
variable for smoking status: one group containing those who smoked regularly (at least 1 
cigarette per day for >3months) during ages 36-45 and the other containing those who either 
never smoked or smoked only outside of that age range.  Alcohol use from ages 40-49 was 
included as an ordinal categorical variable with 6 categories: 1=one for those who never 
drank, 2=one for those who rarely drank (<10 drinks per year), and of the remaining 
participants who had 10 or more drinks for any given year, 4 additional groups were 
established based on the number of drinks they had per week (3=less than 1, 4=1 to 2, 5=3 to 
6 and 6=7 or more drinks per week).  Body mass index at age 40 was used as a continuous 
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predictor and was estimated via linear interpolation of BMI from the baseline study to BMI 
at the follow-up study.  Age at menarche was categorized into ages 9-11, 12-13, and 14-17.  
Menopause before age 46 in a mother and/or sister was included as a dichotomous indicator 
of familial/genetic inheritance.  First (whole or part of one) ovary removed before age 40 was 
categorized as yes/no.   
 
3.5.4  Statistical analysis 
Age at menopause (in years), the outcome of interest, was directly modeled using 
linear regression.  To account for the interval censoring, models were fit using the LIFEREG 
procedure in SAS 9.0.  Non-parametric survival curves were generated by fitting a model 
without any exposure or covariates.  The overall distribution of age at menopause was 
examined for symmetry (FIGURE 3.4), and both normal and logistic distributions of the 
error term were explored.  Since the latter gave a better fit to the data, modeling proceeded 
with the assumption of a logistic distribution.   
Separate models for DDE and PCBs, as well as a model that included both chemicals, 
were fitted, controlling for all the aforementioned predictors of age at menopause.  
Sensitivity analysis excluding certain medical conditions, juvenile diabetes and lupus, was 
also conducted to determine whether these would distort the relationship between 
organochlorines and age at menopause.   Regression coefficients and 95% confidence 
intervals were generated.  The regression coefficients were interpreted as the difference in 
mean age at menopause (years) per unit change in the exposure or covariate value.   
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TABLE 3.1  Response rate into North Carolina Menopause Study   
Response  N (% of 877 in NC 
Infant Feeding Study) 
N (% of 726 
eligibles who 
were traceable) 
Not eligible (no DDE/PCBs)^ 12 (1.4%)  
Not traceable * 139 (15.8%)  
Not found  118 (13.5%) 118 (16.3%) 
Refusals  81 (9.2%) 81 (11.2%) 
Deceased  10 (1.1%)     10 (1.4 %) 
Other  5 (0.6%)       5 (0.7%) 
Completed follow-up interview  512 (58.4%) 512 (70.5%) 
Total  877 (100.0%) 726 (100.0%) 
 ^ no tissue sample available for measurement of DDE or PCBs  
 * no name or other contact information required for tracing 
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Table 3.2  Baseline characteristics (N and %) of participants and non-participants in 
the North Carolina Menopause Study  
 
Variables  Non-participants (n=365)* Participants (n=512)* 
Baseline DDE (ug/mL) Median (range) =  
13.0 (1.3-72.1) 
Median (range) =  
12.6 (1.9-180.0) 
 
Baseline PCB (ug/mL)    Median (range) =  
9.3 (4.4-88.8) 
Median (range) =  
10.0 (4.0-69.6) 
 
Age (yrs) 
   16-20 
   21-30 
   >30 
 
25 (7.4) 
249 (73.5) 
65 (19.2) 
 
14 (2.7) 
370 (72.3) 
128 (25) 
 
Race  
   White  
   Black 
   Other  
 
308 (89.5) 
35 (10.2) 
1 (0.3) 
 
495 (96.7) 
15 (2.9) 
2 (0.4) 
 
Weight (kg) 
 
Mean (SD) = 130. 2 (23.0) 
Median = 125 
Mean (SD) = 130.1 (20.6) 
Median = 125 
 
Number of years in school 
   <12 
   12-16 
   >17 
 
20 (5.9) 
266 (78.5) 
53 (15.6) 
 
1 (0.2) 
374 (73.3) 
135 (26.5) 
 
Cigarettes smoked per day 
when not pregnant  
   None  
0-½ pk 
   ½-1 pk 
   >1 pk 
 
 
259 (76.4) 
24 (7.1) 
24 (7.1) 
32 (9.4) 
 
 
434 (85.4) 
23 (4.5) 
19 (3.7) 
32 (6.3) 
 
Beer can per week when 
not pregnant  
   0 
   1-2 
   3-4 
   >5 
 
 
281 (83.1) 
36 (10.7) 
13 (3.8) 
8 (2.4) 
 
 
409(80.4) 
70 (13.8) 
23 (4.5) 
17 (3.3) 
 
Glass of wine per week 
when not pregnant      
   0 
   1-2 
   3-4 
   >5 
 
 
254 (75.4) 
58 (17.2) 
17 (5.0) 
8 (2.4) 
 
 
321 (63.1) 
140 (27.5) 
34 (6.6) 
14 (2.8) 
 
Liquor drink per week 
when not pregnant  
   0 
   1-2 
   3-4 
   >5 
 
 
301 (89.3) 
29 (8.6) 
4 (1.2) 
3 (0.9) 
 
 
410 (80.6) 
80 (15.7) 
13 (2.6) 
7 (1.4) 
 
*some non-participants had missing information on some variables  
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TABLE 3.3  Data collected in the Menopause Study questionnaire 
 
Menstrual cycle history and menopause  
   Age and school grade when had first period  
   Any menstrual periods (not spotting) in past 12 months  
   Age and date (mon/yr) of last menstrual period  
   For those with no periods in past 12 months, the reason for amenorrhea 
   Menstrual cycle length and irregularity in 12 months before the last menstrual period  
   Night sweats, hot flash, vaginal dryness in the 2 years before the last menstrual period 
 
Pregnancy and breastfeeding history 
   Currently pregnant  
   Number of times pregnant  
   Outcome of current and previous pregnancy 
   Age and date (mon/yr) pregnancy ended  
   Ever breastfed and number of weeks breastfed current and previous child    
 
Medical and family history  
   Age of diagnosis of autoimmune diseases, including juvenile diabetes and lupus 
      Currently taking medications for those diseases (for diabetes, start of insulin use)  
   Mother and/or sister had natural menopause at or before age 46       
 
Surgery and cancer treatment 
   Ever had a hysterectomy and/or oophorectomy 
      Age, date (mon/yr), and season of surgery  
      Number of ovaries removed at surgery, if any 
   Ever had chemotherapy / radiation 
      Age and date (mon/yr) of treatment      
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TABLE 3.3 (continue) 
 
Birth control hormones and hormone replacement therapy (HRT)  
   Ever used oral contraceptives, Norplant or Depo-Provera for any reason 
      Age, date (mon/yr), and season started and ended use for each episode of use 
      Did the start of use occur before or after the last menstrual period 
      For those using birth control >35 years of age, reason for use (including menopause) 
   Ever used female hormones other than birth control  
      Age, date and season started and ended use for each episode of use  
      Did the start of use occur before or after the last menstrual period 
      Did a menstrual period occur within 12 months before started use and was it regular   
 
Smoking 
   Ever smoked regularly (>1 cigarette / day for >3 months) 
   On average, smoked regularly in past 3 months  
   Age started smoking regularly & age stopped smoking for >1 year, per smoking episode 
   Number of cigarettes smoked per day between ages 30-49 
 
Alcohol use 
   Ever drank in your forties 
   Number of years drank >10 drinks per year between ages 40-49 
   Number of alcoholic drinks per week between ages 40-49 
 
Height and weight  
   Height (feet and inches) 
   Current weight (pounds); if unknown, then categories of weight 
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TABLE 3.4 Derivation of serum subsets for organochlorine and hormone analysis  
Group # women DDE/PCB (Study Aim 1) Hormones (Study Aim 2) 
  % 
chosen 
# 
chosen 
# 
assayed 
% 
chosen 
# 
chosen 
# 
assayed 
1 41 30% 12 11 100% 41 36 
2 39 30% 12 10 100% 39 33 
3 107 30% 32 28 100% 107 95 
4 325 30% 98 77 15% 49 39 
Total 512  154 126  236 203 
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TABLE 3.5 Concentrations of PCB congeners as proportion of total PCBs at follow-up, n=126* 
PCB 
congener 
Mean 
concentration, 
wet weight 
Mean as % of 
total mean 
concentration 
Mean 
concentration, 
lipid adjusted 
Mean as % of 
total mean 
concentration 
N (%) non-
detects  
PCB128 0.0002 0.02 0.0190 0.02 125 (99.2) 
PCB101 0.0023 0.29 0.3571 0.29 123 (97.6) 
PCB52 0.0031 0.39 0.5397 0.45 124 (98.4) 
PCB105 0.0083 1.04 1.1206 0.92 87 (69.0) 
PCB183 0.0115 1.44 1.6556 1.37 66 (52.4) 
PCB28 0.0174 2.18 2.8817 2.38 112 (88.9) 
PCB99 0.0359 4.50 5.4563 4.50 22 (17.5) 
PCB156 0.0367 4.61 5.6111 4.63 11   (8.7) 
PCB187 0.0510 6.40 7.6770 6.33 3   (2.4) 
PCB170 0.0552 6.92 8.3778 6.91 2   (1.6) 
PCB118 0.0678 8.50 10.2135 8.43 3   (2.4) 
PCB138 0.1180 14.81 17.9524 14.81 2   (1.6) 
PCB180 0.1714 21.51 26.0714 21.51  0      (0) 
PCB153 0.2183 27.38 33.2730 27.45 1   (0.8) 
Total 0.7970 100.00 121.2063 100.00  
* Assume those below the limit of detection have a value of zero 
                
  
92
 
TABLE 3.6 Formulas for transforming baseline organochlorine measures (into measures that are comparable to those at 
follow-up) 
Unit of 
analysis 
Organo-
chlorine 
Detectable (D) 
or non-
detectable (ND) 
sample 
Baseline 
measure 
used  
Account for 
change in 
quantitation 
method 
Convert 
composite to 
serum equivalent 
for non-detects 
Account for 
lipid rise 
during 
pregnancy  
Account for 
difference in 
milk lipid and 
serum lipid   
D Serum   x 0.7  DDE 
ND Composite  x 5.0071367 x 0.7  
D Serum x 0.236127  x 0.7  
Wet weight  
(ug/L serum) 
PCB 
ND Composite x 0.236127 x 5.4120890 x 0.7  
D Composite    / 1.5 DDE 
ND Composite    / 1.5 
D Composite x 0.236127   / 1.5 
Lipid-
adjusted 
(ug/g lipid) PCB 
ND Composite x 0.236127   / 1.5 
Comp = “composite” measure representing milk at birth , x=multiplication , /=division 
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FIGURE 3.1 Comparison of PCBs using the follow-up quantitation method to PCBs 
using baseline converted to follow-up method, n=10  
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FIGURE 3.2 Comparison of actual serum DDE at birth to those estimated by 
converting composite measures, n=870 with detectable serum levels 
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FIGURE 3.3 Comparison of actual serum PCBs at birth to those estimated by 
converting composite measures, n=762 with detectable serum levels 
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TABLE 3.7 Hormone algorithm for defining menopausal status (at the blood draw) 
Step Hormone  Premenopaual Postmenopausal 
1 FSH <15 IU/L  X   
 FSH >40        X 
 
2 15<FSH<40  and 
  E2 <60 pg/mL    X  
  E2 >100   X 
  
3 15<FSH<40  and  60<E2<100  and 
  FSH/LH ratio <1  X  
  FSH/LH ratio >1    X 
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TABLE 3.8  Menopausal status and censoring for survival analysis 
____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
Categories Age at menopause  
____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
Currently pregnant  Censor at interview  
 
Missing date of LMP* Censor at return of menses following 
  last pregnancy  
 
Radiation or chemotherapy began within 
12 months prior to or following the LMP  
and before any hysterectomy AND  
 - post-menopausal by FSH/LH/E2 Censor at LMP  
 - pre-menopausal by FSH/LH/E2 Censor at LMP  
 - no FSH/LH/E2 Censor at LMP  
 
Hysterectomy before LMP + 12 months  
with any part of an ovary maintained AND  
 - post-menopausal by FSH/LH/E2 Interval censor between LMP and blood draw 
 - pre-menopausal by FSH/LH/ E2 Censor at blood draw  
 - no FSH/LH/ E2 Censor at LMP  
 
Both ovaries removed before LMP + 12  
months AND 
 - post-menopausal by FSH/LH/E2 Censor at LMP  
 - pre-menopausal by FSH/LH/E2 Censor at blood draw^  
 - no FSH/LH/E2 Censor at LMP  
 
LMP <12 months prior to interview AND 
 - post-menopausal by FSH/LH/E2 Natural menopause at LMP  
 - pre-menopausal by FSH/LH/E2 Censor at blood draw  
 - no FSH/LH/E2 Censor at LMP   
 
LMP >12 months prior to interview AND 
 - post-menopausal by FSH/LH/E2 Natural menopause at LMP  
 - pre-menopausal by FSH/LH/E2 Censor at blood draw  
 - no FSH/LH/E2 Natural menopause at LMP  
___________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
^ Interview data suggests she is post-menopausal, while her hormone data (FSH=22, LH=11.14 and 
E2=162.45) suggests pre-menopausal.  Assume her hormone data is correct.    
* LMP – last menstrual period
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FIGURE 3.4 Survival curve of age at menopause (no covariates), n=512 
 
 
  
4. MANUSCRIPT 1. DDE AND PCBS: INTRA-INDIVIDUAL CHANGES, 
CORRELATIONS AND PREDICTORS  
 
4.1 Abstract 
BACKGROUND:  Dichlorodiphenyldichloroethane (DDE) and polychlorinated biphenyls 
(PCBs) are widespread environmental contaminants that have been postulated to increase the 
risk for neurodevelopmental delay, miscarriage, early menopause, and other health outcomes.  
Studies assessing the effect of organochlorine exposure often can only measure 
organochlorine levels once, such as at study enrollment. A single measure might not reflect 
the exposure levels at an etiologically relevant time period.   
OBJECTIVE:  Our aim was to model the temporal changes in DDE and PCBs and the 
predictors of those changes over a follow-up period spanning approximately 25 years..   
METHODS:   Interview data and DDE/PCB measures were collected from 123 women 
enrolled in a baseline study from 1978-1982 and followed up in 2003-2004.  Baseline and 
follow-up organochlorine levels were compared using Spearman correlations (rs) and 
predictors of the rate of change in log concentration were evaluated using linear regression 
models.   
RESULTS:  While serum concentrations dramatically declined (median follow-up to baseline 
concentration ratio was 16% for DDE and 45% for PCBs), baseline and follow-up measures 
were strongly correlated for DDE (rs=0.72) and moderately correlated for PCBs (rs=0.43).  
Prediction of follow-up PCB levels was substantially improved (rs=0.75) with data on initial 
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concentration, length of lactation, baseline body mass index and percent change in body fat, 
while DDE prediction improved slightly (rs=0.83) with data on lactation and baseline body 
mass index.   
CONCLUSION:  Our results suggest that a single organochlorine measure provides 
considerable information on relative ranking at distant times.  Furthermore, predictors such 
as initial concentration, length of lactation, baseline body mass index and percent change in 
body fat can increase the predictive power, particularly for PCBs.   
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4.2 Introduction 
Extensive use of the pesticide, dichlorodiphenyltrichloroethane (DDT), beginning in 
the 1940s and the industrial chemical, polychlorinated biphenyls (PCBs) beginning in 1929, 
have led to their widespread distribution in the environment.  Despite their ban since the 
1970s, PCBs and the DDT metabolite, dichlorodiphenyldichloroethane (DDE), remain 
ubiquitous, raising concerns over their environmental and public health impact.  Many 
studies have evaluated associations of these compounds with human health effects, including 
neurodevelopmental delay [1, 2], miscarriage [3, 4], and earlier menopause [5, 6], although 
clear associations have not been established.    
Studies assessing the effect of these organochlorines on risk of chronic diseases or 
diseases with long latency periods often can only measure levels once; for example, they may 
be measured at enrollment into a prospective study of disease incidence.  While a single 
measure reflects exposure accumulation and excretion of a compound up to the time of 
sampling, it may not provide an accurate picture of exposure level at a time of etiologic 
relevance.   
The objective of this paper is to examine the ability to predict changes in 
organochlorine levels from baseline forward in time over a period of decades.  Few studies to 
date have assessed long-term intra-individual changes in DDE or PCB concentrations and the 
predictors of those changes.  These longitudinal studies [7-12] span approximately 2 to 10 
years, and most have limited covariate data.  Our study uses information collected from 
women who had enrolled in a baseline study of organochlorines (from 1978-1982) and were 
followed for approximately 25 years.    
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4.3 Methods  
Study population  
 From 1978-1982, pregnant women (n=877) from North Carolina were recruited into 
the baseline study of organochlorines and child development [13].  Around the time of 
delivery, a questionnaire including demographics, pre-pregnancy weight, reproductive and 
medical history was administered; maternal and cord bloods, placenta and breast milk were 
also collected for organochlorine determination.  Additional samples were collected at 
subsequent study visits, including blood at the 6 week visit and milk periodically as long as 
the child was breast-fed.  
In 2003-2004, women were traced and invited into a follow-up study on menopause.  
Of 719 traceable women, 513 (71.3%) participated.  Additional data including reproductive 
and lactation history (covering all pregnancies), height and current weight were obtained via 
a telephone-administered questionnaire.   
A sample of 126 individuals, constituting 82% of a 30% random sample of follow-up 
participants who were selected for a blood draw, had DDE/PCB assessment.  Of these, 123 
had a serum organochlorine measure at delivery from the baseline study and will be the 
subjects for the current study.  One individual had missing pregnancy data on the follow-up 
questionnaire and was excluded from our predictive modeling.  Informed consent and 
Institutional Review Board approval were obtained for both baseline and follow-up studies.   
 
Laboratory Assays 
At baseline, p,p’-DDE and PCBs were assayed using packed column-gas 
chromatography with electron capture detection.  PCBs were quantified as the sum of two 
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peaks on a chromatogram [14].  The coefficients of variation were <12% [14].  Due to the 
highly variable fat content in breast milk, milk concentrations were expressed as grams of 
organochlorine per gram of lipid, while concentrations in other tissues were reported per 
gram of tissue.   
At follow-up, organochlorines were assayed using gas chromatography coupled with 
mass spectrometry (GC-MS); coefficients of variation were 5.1% for DDE and 3.5%-11.4% 
for various PCB congeners.  Fourteen congeners were quantitated; for this study, we focused 
on the total of 8 congeners (PCB# 99, 118, 138, 153, 156, 170, 180, and 187) having the 
lowest proportion of non-detects (<18%, compared to 52-98% for the remaining 6 congeners: 
PCB-28, 52, 101, 105, 128, and 183) and the highest relative abundance (together comprising 
~94% of total PCBs measured).  Total lipids were also estimated from total cholesterol, 
phospholipids and triglycerides using the Phillips et al. approach [15], thereby allowing 
concentrations to be expressed per gram of lipid.  A validation study shows that this approach 
gives values very similar to those obtained using the standard gravimetric lipid analysis [16]. 
 
Accounting for change in PCB quantitation methods 
Though the assays have changed since the baseline study, DDE quantitation (which 
involves measurement of a single peak) was the same.  However, PCB quantitation methods 
used at baseline differed from those used at follow-up and do not produce directly 
comparable results. To convert baseline PCB concentrations into their follow-up equivalents, 
we used data from 10 baseline milk samples reanalyzed by GC-MS [17].  Baseline levels 
were multiplied by the median ratio (0.236127) of concentration using the follow-up method 
to concentration using the baseline method.   
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Handling non-detects  
One individual at baseline had non-detectable serum DDE and 18 (14.6%) had non-
detectable serum PCBs.  Serum organochlorine concentrations below the limit of detection 
(LOD) at baseline were assigned estimated values using measurements from all available 
specimens at baseline.  The concentrations from each specimen were previously scaled to 
reflect the concentration in milk lipids at birth of the index child and then averaged to create 
a composite measure for each woman [13].  For this analysis, these composite measures were 
converted into their approximate serum equivalents by multiplying by the median ratio of 
serum to composite concentrations (5.0071367 for DDE and 5.4120890 for PCBs) obtained 
from members of the baseline population with detectable serum values.  To evaluate the 
validity of this imputation, we looked at estimated and actual amounts among those with 
detectable concentrations in serum at delivery: mean % difference and standard deviation 
were 6.1 + 36.9 for DDE and 3.8 + 24.3 for PCBs.  Pearson and Spearman correlations were 
high between estimated and observed values for both DDE (0.90 and 0.91, respectively) and 
PCBs (0.91 and 0.84).  At follow-up, one individual had non-detectable serum DDE, whereas 
28 (22.8%) had at least one non-detectable PCB congener.  Non-detects at follow-up were 
assigned LOD divided by the square root of 2 [18].  Assuming DDE and PCBs are log-
normally-distributed, non-detects would be more accurately represented by this imputation 
approach as opposed to using LOD or 0 as a substitute for non-detects.  Nevertheless, since 
the non-detectable congeners were usually the minor ones, there were only six individuals in 
which the imputation (using extremes of LOD or 0) made a >10% difference in their 
estimated total PCBs.    
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Accounting for pregnancy-related increases 
As serum lipids were not available at baseline, our primary goal was to explore 
changes in wet weight serum organochlorine measures over time. Measures at baseline were 
acquired at or around the time of delivery; however, short-term changes due to pregnancy are 
not the changes of interest.  Given the characteristic rise in lipid content across pregnancy 
[19, 20] and the resulting elevation in organochlorines, wet weight serum measures were 
adjusted to reflect estimated non-pregnant levels.  Based on mean serum total lipids of 5.9 
g/L among more than 2000 non-pregnant Caucasian women, aged 20-34, participating in the 
1976-80 National Health and Nutrition Examination Survey [21, 22] and 8.5 g/L in a 1977-
79 study of 553 pregnant Caucasian women, ages 20-41, at 36 weeks of gestation [20], we 
estimated a 30% increase in total lipids across pregnancy.  To account for this rise, wet 
weight serum concentrations at baseline were reduced by an equivalent amount.   
 
Secondary analysis: Lipid-adjusted serum measures 
Though our primary analysis was based on wet weight organochlorines, we 
conducted a secondary analysis on estimated lipid-adjusted measures.  Lipid-adjusted serum 
concentrations at baseline were estimated by dividing the aforementioned “composite” milk 
values by a correction factor (1.5) that accounts for the difference in lipid concentrations 
between milk and serum.  This factor is the approximate ratio of concentrations in milk lipids 
to those in serum lipids for both DDE [23, 24] and PCBs [23, 25]. 
 
Predictive modeling 
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Although changes in serum DDE and PCB levels over time are driven by complex 
processes, we posit that the time course of such changes during the period under study can be 
reasonably approximated by an exponential decay.  Thus, our basic predictive model was:   
 
[Follow-up] = [Baseline] ∗ exp ( - slope ∗ follow-up time)    
 
which can be re-written as  
 
Log [Follow-up] – Log [Baseline]  = - slope   
follow-up time 
 
where [Follow-up] and [Baseline] are the concentrations, respectively, at follow-up and 
baseline, and “follow-up time” represents years from baseline to follow-up.  Slope represents 
change in log concentrations per unit of follow-up time.  The slope can be affected by 
various determinants, so we modeled it using linear regression; the full model is then of the 
form:  
 
Log [Follow-up] – Log [Baseline]  =  - (α + β1 (X1) . . . + βk (Xk) 
follow-up time 
 
where α is the intercept and βk is the regression coefficient for the k-th predictor, Xk.   
Lactational transfer from mother to infant is an important route of organochlorine 
excretion [13, 26].  In this study, lactation duration, from the follow-up questionnaire, is 
defined as the number of weeks she breast-fed twice or more per day.  Given the diminishing 
role of exclusive breast-feeding as lactation proceeds, the effect of breast-feeding on the rate 
of organochlorine excretion could lessen later in lactation.  Thus, lactation duration was 
treated as a continuous variable but modeled in a piecewise linear fashion with the points 
where the slope changes prespecified as 26 and 39 weeks of lactation.  This was 
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accomplished by defining 3 variables representing the number of weeks of lactation during 
the 3 intervals: 0-26th, 27th-39th, and >39th week of lactation.  The number of weeks of breast-
feeding for each pregnancy from baseline to follow-up was split among these three variables.  
For women with multiple lactations between baseline and follow-up, the lactation 
contribution from each pregnancy was summed.  To illustrate, for a woman with one child 
whose lactation lasted 60 weeks, a value of 26, 13 and 21 weeks was assigned to the first, 
second and third lactation variables, respectively.  If she also had a second child who was 
breastfed for 30 weeks, then an additional 26 weeks was assigned to the first lactation 
variable and 4 weeks to the second, giving final values of 52, 17, and 21 for the three 
lactation variables.  Regressing on these 3 variables produces estimates for the 3 slopes, such 
that the contribution to overall slope of organochlorine decline is:  slope contribution= 
β1(interval 1) + β2(interval 2) + β3(interval 3).  
Previous studies on PCBs and dioxins show that high initial concentration was 
associated with faster decline over time [27, 28].  We included the log of initial (baseline) 
concentration of serum DDE or PCBs as a linear variable in the model.   
Body mass index (BMI) may be associated with an individual’s ability to metabolize 
organochlorines and other xenobiotics, with heavier individuals having slower metabolism 
[29].  Baseline BMI was included in the model as a categorical predictor, with cutpoints at 20 
and 23 kg/m2, due to its narrow distribution.  
Since fat is where organochlorines are sequestered, an increase in body fat without an 
increase in organochlorines might dilute organochlorine concentrations.  Thus, we included a 
measure of percent change in body fat (kg) based on a validated formula for percent body fat, 
which we then converted to body fat by multiplying by body weight [30]:   
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Body fat = [((1.46∗BMI) + (0.14∗age) – 10) / 100] ∗ weight 
 
Usual weight prior to baseline study pregnancy and current weight were obtained, 
respectively, from the baseline and follow-up questionnaires. Percentage change in body fat, 
defined as the difference in body fat from baseline to follow-up divided by baseline body fat, 
was included as a linear variable.   
Mother’s date of birth reflects the secular trend in environmental DDE/PCB levels, 
and hence, the exposure potential.  Calendar date of birth (measured in days with a SAS 
reference date of January 1, 1960) was included as a linear variable in the model.  Another 
possible predictor is baseline maternal age; organochlorine metabolism may change with age.  
However, since age at baseline is highly correlated with date of birth (r=0.97), it was not 
included. 
 
Statistical analysis 
Linear regression models were fit using SAS (version 9.1).  Each predictor was 
examined to obtain the fewest categories needed to adequately characterize the relationship 
between that variable and the slope.  The predictors were added to the model in successive 
order of their assumed strength of effect.  The statistical significance of each potential 
predictor was assessed using the F test.  Spearman correlations comparing actual versus 
model-predicted concentrations at follow-up were used to assess the predictiveness of each 
model.  To illustrate the model fits, model-predicted changes in organochlorine levels were 
plotted along with actual changes for the 122 individuals with non-missing questionnaire 
data.     
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4.5 Results  
The mean age of our study sample at baseline was 29 years.  Other descriptive 
information is shown in Table 4.1.  Among the 122 women with pregnancy data, there were 
207 births during the study period (i.e. from baseline to follow-up, including baseline 
pregnancy) and 39% of these are the only birth during the study period.  Ninety percent of 
the babies were breast-fed, and 52% were breast-fed for more than 26 weeks.  Approximately 
90% of women had a pre-pregnancy body mass index of less than 25 kg/m2 at baseline, and 
all but two had increased (65% with at least a 50% increase) their body fat mass by the time 
of follow-up.   
At baseline, the median wet weight concentrations were 8.5 ug/L for DDE and 1.5 
ug/L for PCBs (TABLE 4.2).  At follow-up, medians fell to 1.2 ug/L and 0.7 ug/L, 
respectively; expressing each follow-up concentration as a percent of her baseline, medians 
were 16% for DDE and 45% for PCBs.  There was a dramatic decline in DDE levels, with 
90% of women having follow-up concentrations <30% of baseline, whereas the variability in 
individual changes was greater for PCBs.  Changes over time in lipid-adjusted measures were 
of similar magnitude.   
The correlations between the two wet weight measures taken more than 20 years 
apart were relatively strong (FIGURES 4.1 and 4.2).  DDE at baseline was highly correlated 
with DDE at follow-up (Spearman r = 0.72), whereas the correlation for PCBs was lower, but 
still sizeable (rs= 0.43). Correlations were similar for lipid-adjusted measures (0.73 and 0.50, 
respectively). 
Higher initial concentration, lactation before 39 weeks, and an increase fat mass was 
associated with an increase in the rate of elimination of wet weight DDE and PCBs, whereas 
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higher baseline BMI tended to decrease the rate of decay (TABLE 4.3).  Similar results were 
found for lipid-adjusted values (not shown).  Mother’s date of birth is not presented, as its 
effect was not significant for either DDE or PCBs.  Table 4.4 shows the statistical 
significance of successive additional terms in the model for the slope and the correlation of 
the resulting predicted follow-up concentration with observed concentration.  Lactation 
duration and baseline BMI were the only statistically significant predictors of DDE slope, 
whereas for PCBs, initial concentration and percent change in body fat were also significant.  
Predicted follow-up concentrations from the full model were highly correlated with actual 
follow-up concentrations for both DDE (Spearman r=0.83) and PCBs (Spearman r=0.75) 
(TABLE 4.4, FIGURES 4.3 and 4.4).   
Figures 4.5 and 4.6 illustrates the predicted changes in DDE and PCB levels, and the 
effect of lactation and baseline BMI.  Overall, there is a rapid decline in DDE and shallower 
reduction in PCB.  The effect of the heaviest versus lightest category of baseline BMI was 
considerable for both DDE and PCBs.  The drop in concentrations as a result of breast-
feeding one child for one year versus no breast-feeding was evident for both compounds, 
although weaker for DDE.  Although not shown, the effect of initial concentration (75th 
versus 25th percentile) on PCB decline was also notable, but the effect of an increase in fat 
mass was comparatively small. 
 
4.6 Discussion 
We found a substantial decline in intra-individual DDE levels over an approximate 25 
year time span (1978-1982 to 2003-2004), with a smaller drop in PCB concentrations.  These 
declines correspond with the reduction in environmental levels since the banning of DDT in 
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1972 and PCBs in 1977 in the United States [31-34].  The larger decline in DDE compared to 
PCBs is similar to those of previous studies conducted among Swedish men from 1991-2001 
[11] and Great Lakes fisheaters from 1982-1989 [8].  In shorter studies, with medians 25.4 
months [10] and 5 years of follow-up [7], the differences in the decline between DDE and 
PCBs were less obvious.  Peak production and the restrictions on usage occurred later for 
PCBs than for DDT and may partly explain the smaller decline in PCBs.  Differences 
between regions and sampling time since organochlorine restrictions may also explain the 
discrepancies between studies.   
Our baseline levels of DDE were highly correlated with those at follow-up (Spearman 
r=0.7). Correlations were lower for PCBs.  Higher correlations for DDE than for PCBs were 
also found in the Wolff et al. study with a median of 25.4 months of follow-up (0.95 versus 
0.83, respectively) [10] and the Hoyer et al. study with a maximum of 7 years follow-up 
(0.79 versus 0.64, respectively) [7].  These differences became less evident when the specific 
congener PCB-153 was assessed; DDE and PCB-153 correlations were respectively 0.92 and 
0.90 in a 1991-2001 study by Hagmar et al. [11] and 0.79 and 0.68 in the Hoyer et al. [7] 
study.  The latter study also showed that correlations varied by PCB congener.  Individual 
congeners could not be evaluated in our study since they were not measured at baseline, and 
the fact that total PCBs is a mix of congeners with different rates of decomposition may 
partly explain the lower correlations in PCBs.   
A number of previous studies have used occupational cohorts or individuals exposed 
to very high, acute doses to estimate half-lives of organochlorines, with estimates being 
approximately 6-10 years for DDE [1, 35] and a few weeks to over 10 years for individual 
PCB congeners [36].  We examined a group of women with protracted, albeit declining, 
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environmental exposures to organochlorines, with attention to the influence of individual 
factors such as lactation and weight fluctuations on DDE and PCB levels.  Based on the 
predicted curves (FIGURES 4.5 and 4.6), the apparent half-lives we predict during this time 
period are approximately 10 years for DDE and 25 years for PCBs, although they vary for 
women with different levels of the predictors.  Since exposure is ongoing, although 
declining, in our study population, half-life estimation is expected to be longer compared to 
the aforementioned studies of occupational cohorts.    
Breast-feeding was important in the elimination of organochlorines in previous 
studies of approximately 2-year [13] and 4-year follow-up [37], and our study indicates that 
the effect of lactation still exists approximately 25 years later.  In our study, lactation beyond 
9 months had much less impact on DDE and PCB levels than the earlier months.  This 
change in effect across windows is expected, given that breast-feeding is likely to diminish in 
the later months as solid foods become an important component of diet.  The impact of one 
year of lactation was more dramatic for PCBs than for DDE (FIGURES 4.5 and 4.6).    
We found an association between higher initial concentration and faster elimination 
of PCBs, consistent with studies among those occupationally exposed [28, 38].  A study of 
701 women environmentally exposed to PCBs (median 31 months follow-up) also reported 
similar findings; those whose PCBs had decreased were over 3 times more likely to have 
higher initial concentrations than those who had maintained their levels [9].  A possible 
explanation for this phenomenon that is most likely in our population is higher induction of 
enzymes at higher doses [27].  Although faster elimination of DDT from adipose tissue was 
associated with higher initial concentration in an experimental study of 3 individuals taking 
varying high level doses of DDT [39], similar data for DDE is not available.   
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Baseline BMI had a strong effect on the rate of change of both DDE and PCBs.  This 
is consistent with BMI-dependent variation in DDE levels in previous studies [10, 12], 
showing a positive association or correlation between a single BMI measure and DDE half 
life.  Sweeney et al. also found a small positive association between baseline BMI and an 
increase in PCB levels [9], although another study did not [10].  It is possible that the effect 
of higher body mass index on the rate of decline may be associated with reduced metabolism 
by xenobiotic-metabolizing enzymes, such as cytochrome P450 (CYP).  CYPs of the 1A, 2B 
and 3A family are most likely involved in the metabolism of various PCB congeners [32, 40, 
41].  Obesity has been associated with decreased activity in CYP 3A4 in several studies [29].   
Studies assessing the influence of weight change on organochlorine change have been 
few, particularly for long term trends [7, 11, 42-44].  Increased fat as a result of weight gain 
may lead to the dilution of organochlorine concentrations, thereby resulting in a negative 
association between body fat and serum organochlorine levels [45].  Our finding of a 
significant effect of fat mass change for PCBs agrees with other studies (with 5 or more years 
of follow-up) that use relative change in body mass index [11] or absolute weight change [7] 
as the predictors of interest.   
Mother’s date of birth, and consequently age, was not a significant predictor of 
change for either DDE or PCBs, which mirrors the lack of association found in other studies 
between age at study entry and change in DDE [11] or PCB levels [9].  As postulated by 
several theoretical models, the exposure patterns over time are a result of complex 
interactions between cohort-related exposures and breast-feeding patterns as well as age-
dependent growth and weight/fat content, dietary intake and composition, and metabolism 
[45, 46].  However, given the small variation in birth year and age in our study population 
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and the fact that everyone was born prior to the ban, we would need a much larger sample 
size to more fully assess the effect of birth cohort and age.    
Although the factors considered in our study help to explain a large portion of the 
variation in DDE and PCB levels over time, other potentially important covariates such as 
changes in diet, particularly fish consumption, were not measured.  A longitudinal study [34] 
conducted from 1980-1995 and a serial cross-sectional study from 1973-1993 [47] of Great 
Lakes fisheaters and “non-eaters” showed fish consumption in the previous year to be 
predictive of PCB body burden.  Likewise, whale blubber consumption in the Faroes Islands 
have been associated with highly chlorinated PCBs [48].   
A limitation of this study is that baseline and follow-up samples were analyzed by 
different labs at different times using different assays.  The most important difference, 
however, is the change in PCB quantitation methods.  To obtain comparable PCB values 
from the old and new techniques, we used conversion factors derived from a set of 10 breast 
milk samples spanning the range of organochlorine values.  Though derived from a small 
sample, our conversion factor seemed reasonable, given the similarity in values and high 
Spearman and Pearson correlations (0.83 and 0.96, respectively) between the original and 
converted values. 
We analyzed both estimated wet-weight and lipid-adjusted measures.  These 
measures involved various assumptions, including those regarding methodology, lipid 
concentration and non-detects.  Similar results for both analyses, nevertheless, provide 
further assurance of our outcome and conclusions.   
“Weeks of lactation” were modeled as three periods of lactation duration, and 
additional cutpoints (at 13 weeks and 52 weeks) did not significantly alter the results.  
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However, “weeks of lactation” alone does not fully capture the extent to which 
organochlorines are being transferred, as there is no data on the amount of milk expressed per 
breast-feeding session or the duration of weaning for all relevant pregnancies.  Additionally, 
for women who fed multiple children, we assumed the effect of lactation would not vary 
across pregnancies; however, it is not possible to evaluate this assumption given the small 
sample size and the lack of organochlorine measurement at each pregnancy.  
While our findings agree with those of previous studies, there are limits to the 
generalizability.  Our study population consists of women who were pregnant at baseline, 
highly educated and mostly Caucasian (95%).  These participants may be different from 
those not studied in terms of their exposure potential, dietary pattern, BMI, and metabolism.  
More importantly, our results may not be generalizable to other regions of the world with 
vastly different exposures, and the findings can be extrapolated beyond the time frame of our 
study (1978-1982 to 2003-2004) only with caution.  Although our assumption of an 
exponential decay is plausible, the shape of the concentration curve between the two 
measurements cannot be determined given only two measures.  Should the shape of the 
concentration curve be better captured by a different form of decay model, then the predicted 
organochlorine values during the period under study can be under- or over-estimated, 
depending on the duration of follow-up.  Multiple measures would be required to more fully 
evaluate the shape.  Nevertheless, our data may be useful to those conducting studies on the 
role of these organochlorines in the development of chronic diseases and have only one 
DDE/PCB measure, at perhaps, an etiologically irrelevant time period.   
We have focused on predicting future levels based on past measurements.  Others 
have attempted to predict past exposure from current concentrations [49, 50].  While our 
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model coefficients cannot be directly used for backward estimations (since the coefficient for 
the predictor, initial (baseline) concentration would be rendered meaningless), our study is 
useful in identifying a handful of important predictors to consider in such estimation models.  
A single measure of DDE is highly predictive of a woman’s relative exposure over a time 
span of approximately 25 years, and can be further improved with data on lactation and 
baseline BMI.  A single measure of PCBs is also predictive of future levels.  Though initial 
concentration and percent body fat change contribute to the prediction of only PCB value, 
lactation duration and baseline BMI are the predominant contributors to both DDE and PCBs 
and information on both of these can be obtained retrospectively.   
To our knowledge, this study which addresses intra-individual variations and 
influences on body burden of DDE and PCBs over time in a general population with 
relatively low level environmental exposure, has the longest duration between serial 
organochlorine measures.  Longer term trends and predictions are of interest for public health 
assessment as well as studies of diseases with long latency periods, where the levels of 
etiologic relevance may be decades apart from the time of measurement.  Future studies to 
replicate or confirm our findings (particular in other epochs and populations) are warranted 
and would benefit from multiple organochlorine measures and additional information on 
other potential predictors.   
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TABLE 4.1 Characteristics of study population, n=123a   
 
Variable  N  (%) 
_________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
Age at baseline (years) 
   19 – 24 24 (19) 
   25 – 29 54 (44) 
   30 – 34 39 (32) 
   35 – 37      6    (5) 
No. of births (baseline to follow-up)  
   1   48 (39) 
   2   56 (46) 
   3 17 (14) 
   6   1   (1) 
No. of babies breast-fed (baseline to follow-up)b 
   0 12 (10) 
   1 45  (37) 
   2 48  (39) 
   3 16 (13) 
   6   1   (1) 
No. weeks of lactation for each birth (baseline to follow-up)b 
   0 – 13 49 (24) 
   14 – 26 50 (24) 
   27 – 39 31  (15) 
   40 – 52 54 (26) 
   53 – 165 23 (11) 
Pre-pregnancy BMI (kg/m2) 
   16.6 – 19.9 47 (38) 
   20 – 24.9  65 (53) 
   25 – 29.9   9    (7)  
   30 – 32.9   2   (2)  
% change in body fat 
   -6 – 0   2   (2) 
   1 – 24 13 (11) 
   25 – 49 27 (22) 
   50 – 99 49 (40) 
   100 – 149 18 (14) 
   150 – 294 14 (11) 
________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
 
a One individual had missing pregnancy and lactation data   
b Among the 207 births delivered to 122 mothers from baseline to follow-up 
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TABLE 4.2  DDE and PCBa concentrations in serum, n=123 
____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
Organochlorine  Percentile  
  -------------------------------------------------------------------------------------------------------------------------------------------_____________________--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------      
 Min 10 25 50  75 90 Max 
____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
Wet weight measures 
DDE (ug/L serum) 
   Baseline   1.3   3.8   5.8   8.5 12.5 19.8 41.0 
   Follow-up   0.01   0.5   0.7   1.2   2.3   3.9 11.0 
   Relative changeb   0.002 0.07 0.10 0.16 0.23 0.29 0.62 
 
PCBs (ug/L serum) 
   Baseline   0.6   0.9   1.2   1.5    2.1   2.7   5.2 
   Follow-up   0.2   0.4   0.5   0.7   1.0   1.2   2.2 
   Relative changeb  0.09 0.25 0.33 0.45 0.65 0.80 1.43 
 
 
Lipid-adjusted measures 
DDE (ug/g lipid) 
   Baseline   0.3   0.7   1.8   1.7   2.5   3.7   7.4 
   Follow-up   0.002   0.1   0.1   0.2   0.4   0.5   1.9 
   Relative changeb   0.002 0.06 0.08 0.12 0.18 0.22 0.56 
 
PCBs (ug/g lipid)  
   Baseline   0.1   0.2   0.2   0.3   0.4   0.5   0.7 
   Follow-up   0.03   0.1   0.2   0.1   0.1   0.2   0.3 
   Relative changeb   0.08 0.21 0.29 0.37 0.51 0.59 0.96 
____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
 
a PCB concentration comprises PCB-99, 118, 138, 153, 156, 170, 180, and 187 
b Relative change = (follow-up concentration / baseline concentration) among all 123 participants 
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FIGURE 4.1  Correlation of baseline with follow-up DDE (ug/L serum), n=123 
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FIGURE 4.2  Correlation of baseline with follow-up PCBs (ug/L serum), n=123 
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TABLE 4.3  Full model coefficients and standard error for slope of DDE and PCB decline*, n=122  
___________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________-_______________________________________________________________________________________________________________ 
Predictors Regression coefficient (S.E.)   
 --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------  
 DDE PCB 
___________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________  
Intercept  -0.061983 (0.0100)  -0.012182 (0.0036) 
Log of initial concentration (ug/L)  -0.004270 (0.0036)  -0.016655 (0.0031) 
Total weeks of lactation in each interval of lactation    
 0-26th  -0.000202 (0.0001)  -0.000201 (0.0001) 
 27th-39th  -0.000295 (0.0003)  -0.000427 (0.0001) 
 >39th   0.000052 (0.0001)  -0.000086 (0.0001) 
Baseline BMI (kg/m2)  
        16.6-19.9    referent  referent 
 20-22.9    0.005467 (0.0053)   0.002533 (0.0029) 
 >23    0.031238 (0.0063)   0.011727 (0.0036) 
Percent change in body fat  -0.008504 (0.0046)  -0.006323 (0.0025) 
_____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
 
 
 
 
 
TABLE 4.4 Description of successive models for slope, n=122 
______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________-___________________________________________________________________________________________________________-___________________________________________________________________________________________________________________________________________________________________________ 
 Statistical significance Spearman correlation for  
 (p-value) of successive  observed and predicted  
 terms in model for slope  follow-up concentration   
 ---------------------------------------------------------------------------------------------------------    ------------------------------------------------------------------------------------------------------------  
Modela Predictors DDE PCB  DDE PCB  
______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________  
I Intercept    n/a    n/a 0.72 0.43      
II Log of initial concentration (ug/L)   0.75 <0.01  0.73 0.46   
III Weeks of lactation   0.05 <0.01  0.75 0.67   
IV Baseline BMI <0.01   0.01 0.82 0.72 
V Percent change in body fat   0.07   0.01 0.83 0.75   
________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
a Each model includes all variables from the preceding model  
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FIGURE 4.3 Plot of predicted versus observed follow-up DDE (ug/L), n=122 
 
 
FIGURE 4.4 Plot of predicted versus observed follow-up PCB (ug/L), n=122 
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FIGURE 4.5  Predicted DDE curve: follow-up concentration as % of baseline, by years of follow-up, n=122 
 
Crosses depict the actual relative change (follow-up/baseline) in levels.  The illustrative lines show the predicted drop in DDE levels over time 
using specific scenarios: each assumes a 60% increase in fat mass and an initial DDE concentration of 1.75 ug/L serum.  Assuming baseline BMI 
of >=23 kg/m2, DDE levels at 26 year of follow-up would be 28% of baseline for those with 1 year of lactation (solid red) and 35% of baseline for 
those with no lactation (dashed red).  Assuming those with a baseline BMI of 16-19.9 kg/m2, DDE levels at 26 year of follow-up would be 12% of 
baseline for those with 1 year of lactation (solid blue) and 15% of baseline for those with no lactation (dashed blue).    
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FIGURE 4.6  Predicted PCB curve: follow-up concentration as % of baseline, by years of follow-up, n=122 
 
Crosses depict the actual relative change (follow-up/baseline) in levels.  The illustrative lines show the predicted drop in PCB levels over time 
using specific scenarios: each assumes a 60% increase in fat mass and an initial DDE concentration of 0.182 ug/L serum.  Assuming  baseline 
BMI of >=23 kg/m2 at baseline, PCB levels at 26 year of follow-up would be 62% of baseline for those with 1 year of lactation (solid red) and 
83% of baseline for those with no lactation (dashed red).  Assuming baseline BMI of 16-19.9 kg/m2, PCB levels at 26 year of follow-up would be 
47% of baseline for those with 1 year of lactation (solid blue) and 62% of baseline for those with no lactation (dashed blue).    
 
  
5. MANUSCRIPT 2. DDE/PCBS AND TIMING OF MENOPAUSE 
 
5.1 Abstract  
BACKGROUND:  There are limited and inconsistent data on the effects of DDE and PCBs 
on the timing of menopause, and previous studies are based on measurements at ages that 
vary and may not be etiologically relevant.   
OBJECTIVE:  Our aim is to evaluate the effect on age at menopause of circulating DDE and 
PCBs, estimated at a standardized age of 40, an age postulated to be sensitive to the effects 
on ovarian aging. 
METHODS:  Subjects were drawn from a previous study of organochlorines and child 
development. Mothers of the children were re-contacted at an average age of 52.4 years.  All 
mothers had organochlorine measurements at ages 26-41 in the original study, and a random 
sample had current measurements. Based on this, serum DDE and PCB levels (ug/L) at age 
40 for all women were estimated using a predictive model.  Interview and ovarian hormone 
data were used to classify menopausal status and define the age at menopause.   
RESULTS:   There was no trend in the unadjusted or adjusted effect estimates across the five 
categories of DDE and PCB exposure, and the estimates were imprecise.  Compared to the 
lowest exposure category, menopause occurred -0.02, 0.4, 0.7, -0.3 years later across 
ascending categories of DDE, and -0.4, 0.4, 0.8, and 0.6 years later across PCB categories.      
CONCLUSION:  Our data do not suggest an effect of relatively low level exposure of DDE 
and PCBs on the age of menopause.  
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5.2  Introduction  
Age at menopause is an important reproductive parameter, with early age at 
menopause being a possible indicator of a damaged ovarian follicular pool or altered 
endocrine feedback loop [1, 2].  In addition to the direct effect on fertility, early age at 
menopause may influence the risk of heart disease [3] and osteoporosis [4].  Various factors 
have been reported to hasten menopause, with smoking most consistently associated with 
earlier age at menopause (~1.5-2 yrs).  The association is usually seen among current rather 
than former smokers, suggesting that the menopausal transition period may be particularly 
vulnerable to the effects of ovarian toxicants [5-7]. Removal of an ovary before age 48 [8] 
and family history of early menopause (before age 46) [9, 10] also have similar or larger 
effects.  Other factors, such as alcohol use, body mass index or weight, and early age at 
menarche, have also been associated with the timing of menopause, but reported effects have 
been small or inconsistent [10-12].  
More recently, p,p’-DDE, a breakdown product of the pesticide 
dichlorodiphenyltrichloroethane (DDT), and the industrial mixture of polychlorinated 
biphenyls (PCBs) have been suggested to influence the timing of menopause.  Four 
epidemiologic studies assessing the relationship between DDE/PCB levels and age at natural 
menopause have been published, showing inconsistent results [13-16].  Organochlorines 
were measured at widely divergent ages (range 21-74 years) among participants in these 
studies.  The objective of our study is to examine whether exposure to environmental levels 
of DDE and PCBs influences the age at onset of menopause.  In contrast to previous studies, 
we estimated organochlorine exposure levels at a standardized age posited to be of etiologic 
relevance.  
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5.3 Methods 
Study population  
Our study population consists of women from North Carolina who were originally 
enrolled in 1978-82 in a baseline study of the effects of organochlorines on the development 
of their infants [17].  Participants were administered a questionnaire that elicited 
demographics, reproductive and medical history; maternal and cord blood samples, as well as 
placenta and breast milk samples, were collected for DDE and PCB determination.  
Of the 877 original participants, 512 (58.4%) were recruited into this 2003-4 follow-
up study.  Sixteen percent lacked information for tracing, 13.5% could not be found, 9.2% 
refused to participate, 1.4% did not have a DDE/PCB measure, and 1.7% had other reasons 
for non-participation.  Follow-up data on demographics, medical and reproductive histories, 
behavioral factors, menstrual cycle function and menopausal status were collected via a 
telephone interview.  All women under age 55 whose menopausal status was unclear (i.e. 41 
who had a hysterectomy but still retained >1 ovary, 39 women currently taking hormone 
replacement therapy (HRT) without a hysterectomy, and 107 women with symptoms of peri-
menopause) plus a 15% random sample of everyone else (regardless of age) were selected for 
a blood draw for measurement of follicle stimulating hormone (FSH), luteinizing hormone 
(LH) and estradiol (E2), to ascertain or confirm their menopausal status.  Informed consent 
was obtained at both the baseline and follow-up study. 
 
Outcome:  Age at natural menopause  
Interview and ovarian hormone (FSH, LH and E2) data were combined to determine a 
participant’s menopausal status and age at natural menopause.  At the follow-up interview, 
  133 
each woman was asked the month and year of her last menstrual period (LMP).  Those with 
no period in the 12 months prior to the interview were asked to identify the reason her 
periods had stopped; choices included natural menopause, ovarian surgery, chemotherapy or 
radiation, use of hormone replacement therapy (HRT) or oral contraceptives (OC), 
pregnancy, breastfeeding or other reason.  The age and/or date of all occurrences of these 
events were also asked.   
For premenopausal and some postmenopausal women, the exact age at natural 
menopause could not be determined, and therefore, their age at natural menopausal was 
censored (see TABLE 5.1).  Among everyone with FSH/LH/E2 data (n=203), classification 
of menopausal status was augmented using the following algorithm.  Women with FSH < 15 
IU/L were considered premenopausal, whereas those with FSH > 40 IU/L, post-menopausal.  
For women with FSH levels between 15 and 40 IU/L, those with estradiol >100 pg/ml were 
considered premenopausal while those with estradiol <60 pg/ml were considered post-
menopausal.  For the remaining women (FSH between 15 and 40 and estradiol between 60 
and 100 pg/ml), those with a FSH:LH ratio above 1 were deemed postmenopausal and those 
with a ratio <1, premenopausal.  Cutpoints were selected to take into account the reported 
distribution and levels of these hormones at different stages of reproductive life [18] as well 
as mimimize misclassification of menopause [19-21]. 
 
Secondary analysis 
In a secondary analysis, we evaluated alternative rules for assigning menopause status 
and age.  These alternative rules accounted for the postmenopausal “breakthrough” bleeding 
caused by HRT use, which can mask the true onset of menopause [22].  If an episode of HRT 
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began before LMP and lasted at least until one year prior to LMP, the following guidelines 
were used to define menopausal status: if FSH/LH/e2 data suggest she is pre-menopausal, 
censor at the blood draw, otherwise, extend the left side of the menopause interval (as 
defined by the rules in TABLE 5.1) to include the whole HRT episode (if it does not 
already).  For a woman who reported using oral contraceptives for menopausal symptoms, 
her last episode of oral contraceptive was treated as HRT.  Multiple episodes of HRT use 
separated by a gap of a year or less were treated as one continuous episode. 
 
Exposure: DDE and total PCBs at age 40 
We are interested in the effect on timing of menopause of baseline DDE and PCBs at 
an etiologically relevant time period in women’s reproductive life.  Analogous to smoking 
[5], we propose that a relevant time period is just prior to the onset of menopause, so we 
chose age 40.  However, baseline measurements were assessed in women at different ages 
(18-41 years, mean of 27), so the baseline exposure levels are not equally reflective of the 
etiologically relevant concentration.  We would expect a woman who was near age 40 at 
baseline to have a measured organochlorine level relatively close in magnitude to the value 
that would have been measured at age 40, while the measured value in a woman who was 
substantially younger than age 40 at baseline may have changed considerably by the time she 
reached age 40.  To make comparable these divergently measured exposure levels, we used a 
predictive model to obtain, for each woman, their estimated organochlorine level at age 40.   
Among a random sample of 123 participants with both baseline and follow-up 
measures, changes in organochlorine concentrations were approximated using an exponential 
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decay model, whereby the slope represented the change in log concentration from baseline to 
follow-up per year of follow-up time (see Manuscript 1).   
 
Log [Follow-up] – Log [Baseline]  = - slope   
follow-up time 
 
Slope was allowed to be influenced by various determinants, including initial 
(baseline) concentration, lactation duration, baseline BMI, and percent change in body fat 
from baseline to follow-up.  Model-predicted levels at follow-up and actual follow-up levels 
were highly correlated: Spearman correlation coefficient of 0.83 for DDE and 0.75 for PCBs.  
This model was used to predict organochlorine levels at age 40 for our entire sample.  
Further, the estimated values at age 40 were highly correlated with those estimated at age 20 
(0.92 for DDE and 0.89 for PCBs) and 30 (0.97 for DDE and 0.94 for PCBs).   
Estimated organochlorine levels at age 40 were categorized into 5 groups.  We used a 
natural cutpoint close to the upper 10th percentile for the highest category, and approximately 
evenly divided the remaining concentrations into 4 additional ranges (TABLE 5.2).   
 
Covariates 
Factors that have been associated with age at menopause and for which information 
was available were included in the model.  Information on cigarette smoking was used to 
construct a dichotomous variable for smoking status, with one group containing those who 
smoked regularly (at least 1 cigarette per day for >3months) during ages 36-45 and the other 
containing those who either never smoked or smoked only outside of that age range.  Alcohol 
use from ages 40-49 was included as an ordinal variable with 6 categories: 1=those who 
never drank, 2= those who rarely drank (<10 drinks per year), and of the remaining 
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participants who had 10 or more drinks for any given year, 4 additional groups were 
established based on the number of drinks they had per week (3=less than 1, 4=1 to 2, 5=3 to 
6 and 6=7 or more drinks per week).  Body mass index at age 40 was estimated via linear 
interpolation of the BMI from the baseline study to BMI at the follow-up study.  Body mass 
index at age 40 was used as a continuous predictor.  Age at menarche was categorized into 
ages 9-11, 12-13, and 14-17.  Menopause before age 46 in a mother and/or sister was 
included as an indicator of familial/genetic inheritance.  First (whole or part of one) ovary 
removed before age 46 was categorized as yes/no.   
 
Statistical analysis 
Age at menopause, the outcome event, was modeled using linear regression.  Our data 
were censored; menopause for an individual occurred either at a particular age, after a certain 
age (right censoring) or between two ages (interval censoring).  In order to account for the 
censoring, models were fit using the LIFEREG procedure in SAS version 9.1 (Cary, North 
Carolina).  Error distributions were assumed to be logistic, as this provided a better fit.  
Separate models for DDE and PCBs, as well as a model that included both 
organochlorines, were fitted, controlling for all the aforementioned predictors of age at 
menopause.  Sensitivity analysis excluding certain medical conditions, juvenile diabetes and 
lupus, was also conducted to determine whether these would distort the relationship between 
organochlorines and age at menopause.   
 
5.5 Results  
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The mean and median ages at menopause were computed, taking into account 
censoring, and were 51.6 years and 51.7 years, respectively; quartiles were 49.5 and 54.5.  
Computation of mean age at menopause without taking into account censoring (that is, 
estimation of mean age at menopause only among women who reported natural menopause) 
would lead to a downward bias in the reported age, since women who would have had later 
menopause (i.e. those who are right censored) would be excluded.  To illustrate, among the 
188 women who reported natural menopause in our study, the mean age at menopause was 
49.2 years.  
Table 5.1 shows that by the time of the follow-up interview, 286 (55.9%) participants 
could be classified as post-menopausal; of these, 251 could be assigned an exact age at 
menopause, while the remaining 35 could not. Of the 512 women, 51 women had an ovary-
conserving hysterectomy prior to one year past LMP; of these, 25 could be classified as post-
menopausal based on ovarian hormones, 11 were pre-menopausal, and 15 had uncertain 
status. Though not shown, 103 (20.1%) participants had taken hormone replacement therapy 
or oral contraceptives for menopausal purposes.   
The mean age of our study population was 52.4 years (TABLE 5.2).  Median baseline 
concentrations were 8.5 ug/L for DDE (range 0.8-1.26; skewness=5.5) and 1.5 ug/L (range 
0.2-11.5; skewness=3.3) for PCBs.  The estimated median levels at age 40 were 3.6 ug/L for 
DDE (range 0.3-67.3; skewness=6.1) and 1.1 ug/L for PCBs (range 0.1-5.9; skewness=1.9).  
Approximately a third of participants had smoked, with 13% smoking during ages 36-45.  
Most women (60%) drank alcohol at least once a week and 23% drank more than 3 drinks 
per week.  The mean estimated BMI at age 40 was 24.2 kg/m2 (range = 17 to 47 kg/m2) and 
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the median age at menarche was 12.  About 18% had a family history of early menopause 
whereas only 3% had a single ovary removed by age 40. 
Overall, survival curves for the various categories of DDE and PCBs largely appear 
to overlap, although there was some suggestion of an increase in the age at menopause for 
the upper 2 categories of PCBs (FIGURES 5.1 and 5.2).  After controlling for the other 
covariates, no discernible effect of either DDE or PCBs was seen (TABLE 5.3).  There was 
no pattern to the estimates and the confidence intervals all included zero.  Similar results 
were found if the alternative definitions of menopause, accounting for HRT, were used (data 
not shown).  Removing the 10 women with lupus and/or juvenile diabetes did not change the 
conclusions (not shown). 
As shown in Table 5.3, smoking between the ages of 36-45 accelerated the timing of 
menopause by 8 months.  Furthermore, although the data is not shown, the effect of smoking 
on age at menopause was dose dependent (11 months earlier menopause for those smoking a 
cigarette pack or more a day, on average, compared to 7 months earlier for those smoking 
less than a pack per day), and smoking only outside of ages 36-45 had little effect (0.8 
months later menopause).  As also shown in Table 5.3, age at menopause was influenced by  
family history of early menopause (1.8 years earlier) and ovary removal before age 40 (1.5 
yrs earlier).   
  
5.6 Discussion 
Our data do not provide evidence for the influence of DDE and PCBs on timing of 
menopause.  Akkina et al. suggested an effect for DDE; Hispanic women (ages 42-74) with 
the highest quintile of exposure (>23.6 ppb) had an adjusted mean age at natural menopause 
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of 1.7 years earlier (p=0.13) compared to those in the lowest quintile (<5.5 ppb) [14].  
However, there was no pattern to the relationship across the remaining quintiles of exposure.  
In contrast, the Cooper et al. study found a dose-dependent effect of DDE among 1407 breast 
cancer cases and controls (median age of 50, range 21-74), with the upper 10th percentile of 
DDE exposure (>2.77ug/gm lipid) having an approximately 1 year earlier median adjusted 
age at menopause compared to those in the bottom 50th percentile 9<0.9 ug/gm) [13].  The 
magnitudes of exposure studied by Cooper et al. tended to be substantially higher than those 
of women in our study.  Using the cutpoints for categorizing (lipid-adjusted) serum DDE in 
the Cooper et al. study, few people in this study were classified in the upper exposure 
categories (TABLE 5.4).  Therefore, this study may have little power to evaluate whether 
exposures of the magnitude studied by Cooper et al. in their highest exposure groups were 
associated with early menopause.    
Our lack of a PCB effect was similar to that in the Cooper et al. study [13] as well as 
two other studies [15, 16].  One study [16] was conducted among 356 PCB-poisoned 
Taiwanese women, ages 30-59, and their 312 age-matched neighborhood controls, ages 30-
59, and did not adjust for any covariates or potential confounders.  The other study [15] of 
874 women (average age 36.2 years, range 24-60) had a preponderance (55%) of women 
with PCB levels at or below the limit of detection (5 ppb).   
Some women with uncertain menopausal status (due to HRT use or surgical 
menopause) were excluded from analysis in two studies [13, 14]; this may bias the results if 
those excluded were systematically different from participants with respect to their age at 
menopause and exposure levels.  Our methods allowed all recruited women to be included in 
our analysis, thereby avoiding any such biases and maintaining the size of our study.  The use 
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of data on endogenous hormone levels as a supplement to interview data further improved 
our assessment of current menopausal status.  
DDE and PCBs could influence the timing of menopause via a multitude of plausible 
mechanisms.  Repeated exposure to p,p’-DDE has been shown to decrease estrogen 
production in porcine granulosa cells [23].  Whether this might influence age at menopause is 
unknown.  p,p-DDE also has anti-androgenic properties [24].  The reported effects of 
androgens varies, and according to recent reports, may depend on the stage of development 
of the follicle [25-27].  While androgens have been reported to enhance follicular atresia in 
immature rats [28, 29] and reduce the number of large follicles [30], recent data in animals, 
including rhesus monkeys, show that androgens, such as testosterone, stimulate the transition 
from primary to secondary follicles and growth of preantral and small antral follicles [27, 31, 
32] in a dose-dependent fashion [25, 26], and that the stimulatory effect is abrogated by 
flutamide, an anti-androgen [26].  Menopause is linked to the exhaustion of these early 
primordial follicles [33], so if androgens increase the rate of their development, early 
menopause might ensue.  The anti-androgenic effects of p,p’-DDE would therefore be 
hypothesized to delay menopause. 
PCB congeners, on the other hand, have estrogenic (i.e. PCB-52, 99, 153) and/or anti-
estrogenic properties (i.e. PCB-105, 118) [34] and may lead to premature menopause via the 
binding and activation of aryl hydrocarbon receptor (AhR)--the same mechanism through 
which smoke-related toxicants [35] and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) may 
exert their effects (TCDD) [36].  AhR binding induces the estrogen-metabolizing enzyme, 
cytochrome p4501A1 [37].  Some PCBs (i.e. PCB-118, 138, 156, and 170) have AhR 
binding capabilities and hence dioxin-like toxicity [38, 39].  Chronic low dose exposure to 
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TCDD has been reported to hasten reproductive senescence in female rats via induction of a 
dose-dependent loss of normal cyclicity and estradiol levels, despite a lack of depletion to 
follicular reserve [36, 40].  Evidence in humans is not clear; one epidemiologic study of 
TCDD showed an inverted U-shape dose response relationship between TCDD and risk of 
early menopause among women accidentally exposed to high levels of TCDD [41].   
An advantage of the current study is that we were able to standardize DDE and PCB 
levels to a common age posited to have heightened sensitivity to ovarian toxicants.  We 
estimated organochlorine values at age 40, around the time of menopausal transition.  
Theoretical models based on biologic data suggest that the rate of atresia in the resting pool 
of primordial follicles during reproductive life, rather the number of oocytes one is born with, 
has a greater influence on hastening the age at menopause [42].  It is possible that exposures 
to DDE and PCBs could increase the rate of atresia during menopausal transition [2, 43]. 
This hypothesis is supported by the literature on smoking and age at menopause, which 
shows a greater impact of smoking near the time of menopause than of smoking earlier in life 
[5-7].  However, as long as the same age is used for all participants, choosing a different age 
for exposure assessment is not likely to change the results, as the estimated values at age 40 
were highly correlated with those estimated at age 20 and 30.  
We did not evaluate PCB congeners grouped by their various biologic and estrogenic 
properties [44] nor did we assess the effect of other DDT metabolites due to their relatively 
low abundance, and this may have contributed to our not finding an effect.  However, we 
were able to detect effects for smoking, family history of early menopause, and ovary 
removal that are consistent with that seen in previous studies [7-9, 11, 45, 46].  Similar 
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findings using the two definitions for menopause, with and without consideration of HRT 
use, further reassure us of our results.    
This study has some limitations.  Given our limited ability to find and enroll the 
participants from the baseline study (58% enrolled), selection bias is possible.  Participants 
were slightly older (mean age of 28.1 years versus 26.6 years), with a slightly higher 
proportion having over 17 years of education (26.5% versus 15.6%) and of White race 
(96.7% versus 89.5%).  However, it is reassuring that the median baseline organochlorine 
values for participants and non-participants were similar for both DDE (8.5 and 8.6 ug/L 
serum, respectively) and PCBs (1.5 ug/L serum each).  Self-reported age at menopause can 
be poorly recalled, and validity of recall can decrease with increasing number of years since 
LMP [47].   In our study, poor recall is unlikely given the relatively short interval between 
LMP and the follow-up interview or blood draw, among 251 women with natural menopause 
(median 2.7 years, range 0-25 years; 90% have <9 years interval).    
Our hormone measures were not timed to the menstrual cycle; however, use of an 
algorithm that encompasses all three ovarian hormones (FSH, LH and E2) would increase the 
discriminating power for determining menopausal status, as compared to FSH alone.  
However, for those taking HRT, it is still possible that menopausal status could be 
misclassified using this algorithm, given that introduction of exogenous estrogen can 
artificially decrease the FSH levels, thereby, causing some postmenopausal women to be 
classified something other than postmenopausal.  Among women with a bilateral 
oophorectomy participating in the National Health and Nutrition Examination Study 
(NHANES), the same proportion (~85%) of women taking HRT and women not taking HRT 
had elevated FSH levels defined as more than 20 IU/L [46].  In contrast, 52% of those taking 
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HRT and 67% of those not taking HRT had FSH levels above 40.  In the North Carolina 
Menopause Study, 33 of 39 women who were currently taking HRT had hormone measures.  
Of these, 25 had FSH>40 IU/L and were assumed to be correctly defined as postmenopausal, 
whereas 4 individuals had FSH<15 IU/L and were assumed to be correctly defined as 
premenopausal, given the findings in NHANES.  Only the remaining 4 individuals (12% of 
those taking HRT) had 15<FSH<40, and thus, may have been subject to misclassification of 
menopausal status.  Exclusion of these 4 women did not alter the study conclusions. 
Our hormone algorithm showed high agreement between the interview and hormone 
data, particularly in the classification of those who were clearly postmenopausal.  Fifty-three 
of the 54 women with >1 year of amenorrhea and hormone data were classified as 
postmenopausal by hormone, while 9 out of 10 women with a bilateral oophorectomy and 
hormone data were classified as postmenopausal by hormone.  For those with less than a year 
of amenorrhea, hormonally-defined menopausal status may be less clear, particularly among 
those undergoing transition and having symptoms of perimenopause (e.g. irregular cycles, 
night sweat, hot flash, vaginal dryness).  Ignoring the hormone data, and instead, censoring at 
the last menstrual period for all women with less than one year of amenorrhea did not change 
the conclusions of this study (not shown).  
Aside from tobacco smoke, research on the role of environmental exposures on the 
timing of menopause has been limited.  Our study is the first to evaluate DDE and PCB 
exposure levels at a standardized and likely etiologically relevant time period of reproductive 
life.  While our data does not provide evidence for an effect of relatively low level exposures 
of DDE and PCBs, it does not negate a possible effect at higher doses.  Further studies with 
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exposures at a more etiologically relevant time period and among higher exposed populations 
are warranted. 
  145 
REFERENCES 
  
1. Santoro, N., J.R. Brown, T. Adel, and J.H. Skurnick, Characterization of 
reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab, 
1996. 81(4): p. 1495-501. 
2. Gougeon, A., R. Ecochard, and J.C. Thalabard, Age-related changes of the population 
of human ovarian follicles: increase in the disappearance rate of non-growing and 
early-growing follicles in aging women. Biol Reprod, 1994. 50(3): p. 653-63. 
3. Rosenberg, L., C.H. Hennekens, et al., Early menopause and the risk of myocardial 
infarction. Am J Obstet Gynecol, 1981. 139(1): p. 47-51. 
4. Kelsey, J.L. and G.S. Berkowitz, Breast cancer epidemiology. Cancer Res, 1988. 
48(20): p. 5615-23. 
5. Cooper, G.S., D.P. Sandler, and M. Bohlig, Active and passive smoking and the 
occurrence of natural menopause. Epidemiology, 1999. 10(6): p. 771-3. 
6. Willett, W., M.J. Stampfer, et al., Cigarette smoking, relative weight, and menopause. 
Am J Epidemiol, 1983. 117(6): p. 651-8. 
7. van Asselt, K.M., H.S. Kok, et al., Current smoking at menopause rather than 
duration determines the onset of natural menopause. Epidemiology, 2004. 15(5): p. 
634-9. 
8. Farquhar, C.M., L. Sadler, S.A. Harvey, and A.W. Stewart, The association of 
hysterectomy and menopause: a prospective cohort study. Bjog, 2005. 112(7): p. 956-
62. 
9. Cramer, D.W., H. Xu, and B.L. Harlow, Family history as a predictor of early 
menopause. Fertil Steril, 1995. 64(4): p. 740-5. 
10. Torgerson, D.J., A. Avenell, I.T. Russell, and D.M. Reid, Factors associated with 
onset of menopause in women aged 45-49. Maturitas, 1994. 19(2): p. 83-92. 
  146 
11. Kato, I., S. Tominaga, and T. Suzuki, Factors related to late menopause and early 
menarche as risk factors for breast cancer. Jpn J Cancer Res, 1988. 79(2): p. 165-72. 
12. Kaczmarek, M., The timing of natural menopause in Poland and associated factors. 
Maturitas, 2007. 57(2): p. 139-53. 
13. Cooper, G.S., D.A. Savitz, R. Millikan, and T. Chiu Kit, Organochlorine exposure 
and age at natural menopause. Epidemiology, 2002. 13(6): p. 729-33. 
14. Akkina, J., J. Reif, T. Keefe, and A. Bachand, Age at natural menopause and 
exposure to organochlorine pesticides in Hispanic women. J Toxicol Environ Health 
A, 2004. 67(18): p. 1407-22. 
15. Blanck, H.M., M. Marcus, and P.E. Tolbert, Time to  menopause in relation to PBBs, 
PCBs,  and smoking. Maturitas, 2004. 49: p. 97-106. 
16. Yu, M.L., Y.L. Guo, C.C. Hsu, and W.J. Rogan, Menstruation and reproduction in 
women with polychlorinated biphenyl (PCB) poisoning: long-term follow-up 
interviews of the women from the Taiwan Yucheng cohort. Int J Epidemiol, 2000. 
29(4): p. 672-7. 
17. Rogan, W.J., B.C. Gladen, et al., Polychlorinated biphenyls (PCBs) and 
dichlorodiphenyl dichloroethene (DDE) in human milk: effects of maternal factors 
and previous lactation. Am J Public Health, 1986. 76(2): p. 172-7. 
18. Speroff, L. and M.A. Fritz, Menopause and the Menopausal transition, in Clinical 
Gynecologic Endocrinology and Infertility. 2005, Lippincott, Williams & Wilkins: 
Philadelphia. p. 621-688. 
19. Creinin, M.D., Laboratory criteria for menopause in women using oral 
contraceptives. Fertil Steril, 1996. 66(1): p. 101-4. 
20. Sowers, M.F., S. Crawford, and B. Sternfeld, SWAN: a multi-center, multi-ethnic, 
community-based cohort study of women and the menopausal transition., in 
Menopause: biology and pathobiology, R.A. Lobo and J. Kelsey, Editors. 2000, 
Academic Press: San Diego. p. 175-188. 
21. Nordin, B.E., R.G. Crilly, D.H. Marshall, and S.A. Barkworth, Oestrogens, the 
menopause and the adrenopause. J Endocrinol, 1981. 89 Suppl: p. 131P-143P. 
  147 
22. Speroff, L. and M.A. Fritz, Postmenopausal Hormone Therapy, in Clinical 
Gynecologic Endocrinology and Infertility. 2005, Lippincott, Williams & Wilkins: 
Philadelphia. p. 689-777. 
23. Wojtowicz, A.K., E.L. Gregoraszczuk, A. Ptak, and J. Falandysz, Effect of single and 
repeated in vitro exposure of ovarian follicles to o,p'-DDT and p,p'-DDT and their 
metabolites. Pol J Pharmacol, 2004. 56(4): p. 465-72. 
24. Kelce, W.R., C.R. Stone, et al., Persistent DDT metabolite p,p'-DDE is a potent 
androgen receptor antagonist. Nature, 1995. 375(6532): p. 581-5. 
25. Vendola, K.A., J. Zhou, et al., Androgens stimulate early stages of follicular growth 
in the primate ovary. J Clin Invest, 1998. 101(12): p. 2622-9. 
26. Yang, M.Y. and J.E. Fortune, Testosterone stimulates the primary to secondary 
follicle transition in bovine follicles in vitro. Biol Reprod, 2006. 75(6): p. 924-32. 
27. Wang, H., K. Andoh, et al., Effect of adrenal and ovarian androgens on type 4 
follicles unresponsive to FSH in immature mice. Endocrinology, 2001. 142(11): p. 
4930-6. 
28. Bagnell, C.A., T.M. Mills, A. Costoff, and V.B. Mahesh, A model for the study of 
androgen effects on follicular atresia and ovulation. Biol Reprod, 1982. 27(4): p. 
903-14. 
29. Conway, B.A., V.B. Mahesh, and T.M. Mills, Effect of dihydrotestosterone on the 
growth and function of ovarian follicles in intact immature female rats primed with 
PMSG. J Reprod Fertil, 1990. 90(1): p. 267-77. 
30. Nandedkar, T.D. and S.R. Munshi, Effect of dihydrotestosterone on follicular 
development, ovulation and reproductive capacity of mice. J Reprod Fertil, 1981. 
62(1): p. 21-4. 
31. Vendola, K., J. Zhou, et al., Androgens promote oocyte insulin-like growth factor I 
expression and initiation of follicle development in the primate ovary. Biol Reprod, 
1999. 61(2): p. 353-7. 
  148 
32. Murray, A.A., R.G. Gosden, V. Allison, and N. Spears, Effect of androgens on the 
development of mouse follicles growing in vitro. J Reprod Fertil, 1998. 113(1): p. 27-
33. 
33. McGee, E.A. and A.J. Hsueh, Initial and cyclic recruitment of ovarian follicles. 
Endocr Rev, 2000. 21(2): p. 200-14. 
34. Hansen, L.G., Stepping backward to improve assessment of PCB congener toxicities. 
Environ Health Perspect, 1998. 106 Suppl 1: p. 171-89. 
35. Matikainen, T., G.I. Perez, et al., Aromatic hydrocarbon receptor-driven Bax gene 
expression is required for premature ovarian failure caused by biohazardous 
environmental chemicals. Nat Genet, 2001. 28(4): p. 355-60. 
36. Franczak, A., A. Nynca, et al., Effects of acute and chronic exposure to the aryl 
hydrocarbon receptor agonist 2,3,7,8-tetrachlorodibenzo-p-dioxin on the transition to 
reproductive senescence in female Sprague-Dawley rats. Biol Reprod, 2006. 74(1): p. 
125-30. 
37. Safe, S., F. Wang, et al., Ah receptor agonists as endocrine disruptors: antiestrogenic 
activity and mechanisms. Toxicol Lett, 1998. 102-103: p. 343-7. 
38. Safe, S., S. Bandiera, et al., PCBs: structure-function relationships and mechanism of 
action. Environ Health Perspect, 1985. 60: p. 47-56. 
39. Kafafi, S.A., H.Y. Afeefy, et al., Binding of polychlorinated biphenyls to the aryl 
hydrocarbon receptor. Environ Health Perspect, 1993. 101(5): p. 422-8. 
40. Shi, Z., K.E. Valdez, et al., Ovarian Endocrine Disruption Underlies Premature 
Reproductive Senescence Following Environmentally Relevant Chronic Exposure to 
the Aryl Hydrocarbon Receptor Agonist 2,3,7,8-Tetrachlorodibenzo-p-Dioxin. Biol 
Reprod, 2007. 76(2): p. 198-202. 
41. Eskenazi, B., M. Warner, et al., Serum dioxin concentrations and age at menopause. 
Environmental Health Perspectives, 2005. 113(7): p. 858-862. 
42. Thomford, P.J., F.R. Jelovsek, and D.R. Mattison, Effect of oocyte number and rate of 
atresia on the age of menopause. Reprod Toxicol, 1987. 1(1): p. 41-51. 
  149 
43. Richardson, S.J., V. Senikas, and J.F. Nelson, Follicular depletion during the 
menopausal transition: evidence for accelerated loss and ultimate exhaustion. J Clin 
Endocrinol Metab, 1987. 65(6): p. 1231-7. 
44. Wolff, M.S., D. Camann, M. Gammon, and S.D. Stellman, Proposed PCB congener 
groupings for epidemiological studies. Environ Health Perspect, 1997. 105(1): p. 13-
4. 
45. Torgerson, D.J., R.E. Thomas, and D.M. Reid, Mothers and daughters menopausal 
ages: is there a link? Eur J Obstet Gynecol Reprod Biol, 1997. 74(1): p. 63-6. 
46. Cooper, G.S. and J.M. Thorp, Jr., FSH levels in relation to hysterectomy and to 
unilateral oophorectomy. Obstet Gynecol, 1999b. 94(6): p. 969-72. 
47. den Tonkelaar, I., Validity and reproducibility of self-reported age at menopause in 
women participating in the DOM-project. Maturitas, 1997. 27(2): p. 117-23. 
 
  150 
TABLE 5.1 Menopausal status and censoring for survival analysis 1, n=512 
___________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
Categories Age at menopause    N (%) 
____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
Currently pregnant  Censor at interview    1  (0.1) 
 
Missing date of LMP* Censor at return of menses    1  (0.1) 
  following last pregnancy 
 
Radiation or chemotherapy began within 
12 months prior to or following the LMP  
and before any hysterectomy AND  
 - post-menopausal by FSH/LH/e2# Censor at LMP    1  (0.1) 
 - pre-menopausal by FSH/LH/e2 n/a    0  (0.0) 
 - no FSH/LH/e2 Censor at LMP    5  (1.0) 
 
Hysterectomy before LMP + 12 months  
with any part of an ovary maintained AND  
 - post-menopausal by FSH/LH/e2 Interval censor between LMP  25  (4.9) 
  and blood draw  
 - pre-menopausal by FSH/LH/e2 Censor at blood draw  11  (2.1) 
 - no FSH/LH/e2 Censor at LMP  15  (2.9) 
 
Both ovaries removed before LMP + 12  
months AND 
 - post-menopausal by FSH/LH/e2 Censor at LMP    9  (1.8) 
 - pre-menopausal by FSH/LH/e2 Censor at blood draw    1  (0.1)^ 
 - no FSH/LH/e2 Censor at LMP  40  (7.8) 
 
LMP <12 months prior to interview AND 
 - post-menopausal by FSH/LH/e2 Natural menopause at LMP   66 (12.9) 
 - pre-menopausal by FSH/LH/e2 Censor at blood draw   36   (7.0) 
 - no FSH/LH/e2 Censor at LMP 115 (22.5) 
 
LMP >12 months prior to interview AND 
 - post-menopausal by FSH/LH/e2 Natural menopause at LMP   53 (10.4) 
 - pre-menopausal by FSH/LH/e2 Censor at blood draw     1   (0.1) 
 - no FSH/LH/e2 Natural menopause at LMP 132 (25.8) 
 
____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
*LMP – last menstrual period 
#
 FSH/LH/e2 refers to follicle stimulating hormone, luteinizing hormone and estradiol 
^ Interview data suggests she is post-menopausal, but she was categorized as pre-menopausal   
   based on her hormone data (FSH=22, LH=11.14 and E2=162.45).   
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Table 5.2 Characteristics of Menopause Study population, n=512   
___________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
  n  (%)  
__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
Age at follow-up study 
    43.0 – 44.9   15 (2.9) 
    45.0 – 49.9 125 (24.4) 
    50.0 – 54.9 249 (48.6) 
    55.0 – 59.9 110 (21.5) 
    60.0 – 66.3   13 (2.5) 
Estimated DDE at age 40 (ug/mL serum) 
    0.3 – 1.9 133 (26.0) 
    2.0 – 4.2 169 (33.0) 
    4.3 – 6.5 112 (21.9) 
    6.6 – 8.9   47 (9.2) 
    9.0 – 67.3    51 (9.9) 
Estimated PCB at age 40 (ug/mL serum) 
    0.12 – 0.79 128 (25.0)  
    0.80 – 1.13 162 (31.6) 
    1.14 – 1.47 114 (22.3) 
    1.48 – 1.79   53 (10.4) 
    1.80 – 5.91   55 (10.7) 
 Smoking  
    Never smoke  332 (64.8) 
    Smoke only outside ages 36-45 115 (22.4) 
    Smoke during ages 36-45   65 (12.8) 
Drinking during her 40s  
    Never drank   96  (18.7) 
    Drank <10 times per year   115 (22.5) 
    Drank >10 per year but < 1 drink per week 105 (20.5) 
    Drank 1-2 drinks per week   78 (15.2) 
    Drank 3-6 drinks per week   87 (17.0) 
    Drank 7 or more drinks per week   31 (6.1) 
Estimated BMI at age 40 (kg/m2) 
    17.2 – 19.9   68 (13.3) 
    20.0 – 24.9 266 (51.9) 
    25.0 – 29.9 122   (23.8)  
    30.0 – 47.3   55 (10.9) 
Age at menarche 
    9-11 114  (22.3) 
    12-13 293 (57.2) 
    14-17 104 (20.3) 
    Missing     1 (0.2) 
Family history of menopause before age 46 
(in mother and/or sister) 
    No 420  (82.0) 
    Yes   92 (18.0) 
First whole ovary removed by age 40 
    No 497 (97.1) 
    Yes   15 (2.9) 
 
_________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
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FIGURE 5.1 Survival curves for the effect of DDE (ug/L serum) at age 40, n=512 
 
 
FIGURE 5.2: Survival curves for the effect of PCBs (ug/L serum) at age 40, n=512 
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TABLE 5.3 Regression coefficients for effect of DDE and PCBs  
at age 40, controlling for covariates, n=511 
 
Variable  β (95% CI)  
________________________________________________________________________________________________________________  
DDE at age 40 (ug/L serum) 
 0.3 – 1.9 referent  
 2.0 - 4.2 -0.023  (-1.101, 1.055) 
 4.3 – 6.5  0.435  (-0.843, 1.712) 
 6.6 – 8.9  0.675  (-0.982, 2.332) 
 9.0 – 71.7 -0.257  (-1.846, 1.332) 
PCB at age 40 (ug/L serum) 
 0.12 – 0.79 referent 
 0.80 – 1.13 -0.433  (-1.529, 0.662) 
 1.14 – 1.47  0.379  (-0.873, 1.631) 
 1.48 – 1.79  0.786  (-0.869, 2.441) 
 1.80 – 5.62  0.588  (-0.977, 2.153) 
Smoking (between ages 36-45) 
 No  referent 
 Yes -0.677  (-1.858, 0.504) 
Alcohol use  0.074  (-0.177, 0.326)  
BMI at age 40  -0.005  (-0.097, 0.087) 
Age at menarche 
 9-11 Referent 
 12-13  0.059  (-0.834, 0.951) 
 >13  1.125  (-0.038, 2.288) 
Family history (mom and/or sister) 
 No referent 
 Yes -1.852  (-2.806, -0.898) 
First ovary removed (by age 40) 
 No  referent 
 Yes -1.537  (-3.733, 0.659) 
_________________________________________________________________________________________________________________  
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TABLE 5.4  Comparison of DDE & PCB levels in the Menopause Study and the 
  Cooper et al. study 
 
 Cooper et al. Study [13]* Menopause Study^ 
DDE (ug/g 
lipid) 
N Adjusted HR (95% CI) N Adjusted β (95% CI) 
<0.62 699 1.0 282 Referent 
0.62-1.36 311 1.2 (0.9, 1.6) 176 0.917 (0.129, 1.705) 
1.37-2.76 200 1.3 (0.9, 1.8) 46 0.721 (-0.566, 2.008) 
>2.76 138 1.4 (0.9, 2.1) 8 -0.653 (-3.563, 2.258) 
PCB (ug/g lipid) N Adjusted HR (95% CI) N Adjusted β (95% CI) 
<0.36 675 1.0 496 Referent 
0.36-0.52 332 1.0 (0.7, 1.4) 14 1.363 (-1.309, 4.035) 
0.53-0.73 190 1.1 (0.8, 1.5) 1 42.443 (-157615, 157699) 
>0.73 151 0.9 (0.6, 1.3) 1 -5.589 (-19.842, 8.666) 
* HR is hazard ratio 
^ DDE levels at age 40 were estimated with adjustment for 6.39 g lipid (as estimated for 
Caucasian women, ages 36-44 in NHANES study); β is the difference in age at 
menopause (yr); model adjusted for smoking (never and smoke outside ages 36-45 
versus smoking during ages 36-45), ovary removal by age 40, family history before 
age 46, age at menarche, BMI at age 40, and alcohol use in her 40s 
 
  
6. DISCUSSION 
 
6.1 Summary of findings 
This research was partly motivated by the inconsistent results found in previous 
literature pertaining to DDE/PCBs and age at menopause, and the need to address the 
limitation in exposure assessment in these studies.  DDE and PCBs, in previous studies, were 
measured in women with widely divergent ages and oftentimes measured after the onset of 
menopause, a time that is not of etiologic relevance.  In addressing this limitation, the goals 
of this research were to evaluate the long-term dynamics of intra-individual levels of DDE 
and PCBs and, based on this information, assess the impact on timing of menopause from 
these organochlorines, estimated at an age posited to be of etiologic significance.  
This study shows a substantial decline in organochlorine levels from 1978-1982 to 
2003-2004, this decline was more dramatic for DDE than PCBs.  The overall and differential 
declines between these organochlorines were also seen in other studies and may reflect, in 
part, the environmental impact of an earlier ban on DDE as compared to PCBs.   
A single organochlorine measure at a follow-up period of approximately 25 years is 
highly correlated with and predictive of baseline values, particularly for DDE, which is 
consistent with other studies having a maximum of 10 years of follow-up [1-3].  Hence, a 
single measure of DDE, as compared to PCBs, would be a more meaningful indicator of 
exposure at distant times.  Though it is unclear why the correlation is higher for DDE than 
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PCBs, the fact p,p’-DDE is a single chemical whereas PCBs are a mix of congeners with 
variable rates of decomposition may partly explain this finding.   
The results of this study show that prediction of organochlorines can be improved 
with the addition of a few easily collected variables.  Baseline BMI and lactation improves 
the prediction of DDE slightly, whereas these factors along with initial concentration and 
change in fat mass substantially improved the prediction of PCBs.  The discrepancy in the 
explanatory capacity of these variables across organochlorine compounds may reside in the 
fact that temporal measures of DDE are already highly correlated with one another and little 
variability remains to be explained by these additional factors.  Furthermore, the results 
demonstrate the feasibility of using these predictive models for exposure estimation.  
This study shows that the cumulative effect of lactation is still evident decades later 
and is the first to attempt to differentiate the impact of different intervals of lactation 
duration.  The results indicate the earlier weeks (<39 weeks) of lactation is more important 
than later lactation and highlights the need to consider the likely diminishing role of 
breastfeeding as lactation proceeds.    
Higher body mass index is associated with a slower rate of DDE and PCB 
elimination, which is similar to the findings of some previous studies [3-5].  In contrast, an 
increase in fat mass was associated with a faster decline in concentrations.  These results 
suggest that different aspects of weight function differently in the elimination of serum 
organochlorines, and therefore, should be distinguished.  Conceptually, body mass index may 
be a marker of metabolism, whereas fat mass change may be a reflection of passive dilution 
of organochlorines. 
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Initial (baseline) concentration was an important predictor of PCB decline, similar to 
the findings from studies of occupational cohorts [6, 7], and may likely be a function of 
greater enzyme induction at higher doses [8]. In contrast, mother’s date of birth, which was 
highly correlated with maternal age, was not an important predictor for either 
organochlorines.  However, given the small variations in birth year and age, the impact of 
birth cohort and maternal age cannot be more fully assessed. 
There was no evidence for an effect of DDE and PCBs on age at menopause, in both 
unadjusted and adjusted models.  The lack of a DDE effect was inconsistent with a prior 
study by Cooper et al., which reported an earlier age at menopause with DDE exposure [9].  
The Cooper et al. study had a wide age spread (ages 21-74) with a sizeable proportion of 
women who had organochlorines measured after the onset of menopause.  While it is 
possible that there is no biological effect of DDE, it is unclear whether the exposure levels in 
this study may be too low to see an effect.  The magnitudes of exposure studied by Cooper et 
al. in the highest exposure categories tended to be substantially higher than those of women 
in our study.  Therefore, this study may be underpowered to assess whether these higher 
magnitudes of exposure were associated with altered age at menopause.  Since age at 
menopause is a risk factor for various estrogen-related health outcomes (breast and 
endometrial cancers), an impact on age at menopause from DDE and PCB exposure, would 
suggest a biological effect of these organochlorines on the health outcomes.   
One assumption of these analyses was that estimation of organochlorine levels at age 
40 would provide a more biologically-relevant exposure metric than simply using baseline 
measures.  We decided to standardize exposures to values expected to be observed at 40 
years of age, around the time of menopausal transition and an age that is likely to be sensitive 
  158 
to the effects of ovarian toxicants.  Choosing a different age for exposure estimation would 
be unlikely to alter the results of this study as the estimated values at age 40 were highly 
correlated with those at age 20 and 30.   
On the other hand, smoking between ages 36-45, family history of early menopause, 
and unilateral oophorectomy had large effects and hastened menopause by 8 to 20 months.  
Though these results are somewhat imprecise, they are consistent with previous literature.    
 
6.2 Strengths and limitations of Study Aims 1 and 2  
A major strength of the research on intra-individual changes and predictors of change 
in DDE and PCBs is the very long period of follow-up (approximately 25 years) between 
organochlorine measurements.  Previous prospective studies in populations also exposed to 
generally low environmental levels have had less than 10 years in duration between 
measurements.   
Previous studies have not simultaneously assessed the effect of different facets of 
weight measures (i.e. baseline BMI versus percent change in fat mass).  The results of this 
study support the notion that these measures may represent different processes that alter 
serum organochlorine concentrations.  It should be noted that despite the narrow range of 
BMI at baseline, the effect of a single measure of body mass index was impressive.  Whether 
this effect would be stronger at higher BMI remains unclear.   
In contrast to previous studies, lactation was treated as three continuous variables, 
with each representing a different interval of lactation duration (<26th, 27th-39th, and >39th 
week of lactation).  A single continuous measure defined as “weeks of lactation,” does not 
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fully capture the extent to which organochlorines are being transferred, and the results of this 
study indicate that different intervals of lactation reflect different elimination potential.   
In this study, baseline serum organochlorine measures were not directly used, but 
were transformed to account for the change in PCB quantitation technology, the lipid rise 
during pregnancy as well as non-detects.  However, validation of the conversion factors used 
at each stage of the transformation revealed very high correlations and similarity in values 
between estimated and observed measures.     
While the predictive models for DDE and PCBs performed well, as indicated by the 
high correlations between predicted and observed follow-up values, a limitation of having 
only two organochlorine measures and little variability in the number of years of follow-up 
(21-26 years) is the inability to assess the exact shape of the predicted curve.  As with other 
similar compounds (dioxins and polybrominated biphenyls) [10, 11], DDE and PCBs are 
assumed to have an exponential decay.  Nevertheless, if the shape of the concentration curve 
is better captured by a different form of decay model, then the predicted organochlorine 
values during the period under study can be under- or over-estimated, depending on the 
duration of follow-up.  Multiple serial organochlorine measures would be necessary to 
evaluate the shape of the curve between the two study periods. 
There are limits to the generalizability of the study results.  The study population 
consisted mostly of highly educated, Caucasian women residing in North Carolina, who may 
have vastly different exposure potentials, dietary habits, BMI, and rates of metabolism (for 
example, because of genetic differences) than those not studied.  More importantly, as 
measurements were taken after the bans on DDE and PCBs, extrapolation to time periods 
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prior to this study’s time period should be done with extreme caution, as the exposure pattern 
and potential may be very different in the past, particularly prior to the bans.   
 
6.3 Strengths and limitations of Study Aim 3 
A major strength of this research on the role of DDE and PCBs in the timing of 
menopause is the use of a predictive model to assess organochlorine levels at a common age 
that is likely to be of etiologic significance.  In addition to the more appropriate time window 
of exposure assessment, an advantage to this approach is that exposure measures taken in 
women at various ages at baseline can be made more comparable with respect to the 
exposure measure of interest.    
Another strength of this study is the use of ovarian hormone data to supplement the 
classification of menopausal status, and in combination with censoring, further define the 
time period of menopausal experience.  Given the hormone data, all participants were able to 
be included, thereby maintaining the size and precision of the study and avoiding the 
potential selection bias that may have been introduced in previous studies, which excluded 
women with unclear menopausal status (i.e. those currently taking hormone replacement 
therapy or those who had a hysterectomy or oophorectomy).   
Hormone measures, however, were not timed to the menstrual cycle.  Given this 
scenario, our algorithm that incorporates all three hormones would be a better discriminator 
of menopausal status than FSH alone [12], as high FSH levels may be indicative of either 
menopause or a spike during ovulation.  Nevertheless, among those taking hormone 
replacement therapy, misclassification of menopausal status can still occur.  These 
exogenous estrogens can cause a drop in FSH levels [13].  Our analysis indicate that only  4 
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individuals with FSH levels between 15 IU/L and 40 IU/L are likely to be subject to 
misclassification.  Excluding these women from analysis did not change the study 
conclusions. 
 Another aspect of HRT use can cause misclassification of menopausal status.  
Hormone replacement therapy can mask the onset of menopause by causing false bleeding 
that may be mistaken for pre-menopausal menstrual bleeding.  However, the results were 
similar when a sensitivity analysis was conducted, in which censoring began at the start of 
HRT use.   
Optimal hormonal cutpoints were obtained from several studies that evaluated the 
ability of these cutpoints to discriminate menopausal status among those who had clearly 
defined menopausal status (those with a bilateral oophorectomy or having regular cycles) 
[12, 14-16].  In our study, the hormone data performed well with regards to correctly 
classifying (as post-menopausal) women who had a bilateral oophorectomy or had >1 year of 
amenorrhea.  However, validation of the algorithm has not been conducted among those with 
less clearly defined status (those with a simple hysterectomy, having irregular cycles, or are 
within 5 years of their natural menopause).  In our study, there were 12 individuals with less 
than a year of amenorrhea and hormone data, and who did not take HRT, did not have a 
hysterectomy or oophorectomy, did not report irregular menstrual cycles, and did not have 
radiation / chemotherapy: 8 were classified as post-menopausal by hormone and 4 as pre-
menopausal by hormone.  All 8 of the hormally-defined post-menopausal women and one of 
the hormonally-defined pre-menopausal women did, however, report having hot flashes, 
vaginal dryness, and/or night sweats in the past 2 years or self-report having had natural 
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menopause.  In addition, ignoring the hormone data and censoring (at the LMP) those with 
less than a year of amenorrhea did not change the conclusion of this study.  
Menopausal age was self-reported and can be subject to errors in recall.  The validity 
of recall can decrease as the time since the last menstrual period increases [17].  However, 
the follow-up interviews were conducted near the time of menopause (ages 43-66) and poor 
recall is likely minimal.  Furthermore, the ability to recall is not expected to be associated 
with DDE and PCB levels.  
There was a sizeable proportion (42%) of women at baseline who did not participate 
in the follow-up study.  Of these, 70% could not be found or could not be traced due to 
missing contact information.  Although it is unclear whether exclusion of these women is 
associated with age at menopause, it is reassuring that their DDE and PCB levels were 
similar to those of participants.   
  
6.4 Implications  
DDE and PCBs are ubiquitous environmental pollutants, and therefore, their potential 
health effects are of great concern.  The impact of the bans on environmental levels of DDE 
and PCBs is partly reflected in the concomitant drop in serum organochlorines over the two 
study time periods.  Nevertheless, persistence of these compounds and their reported, though 
not established, associations with various health outcomes [18-21] would necessitate the 
continued public health observance of individual body burden.   
High correlations between measures at distant times, particularly for DDE, would be 
of substantial interest to investigators of etiologic studies using only a single organochlorine 
measure at a time not relevant to disease causation or pathogenesis.  Furthermore, this study 
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contributes to the relatively small body of literature on organochlorine exposure estimation 
[22] [23] by identifying additional factors (body mass index, initial concentration, and 
change in body fat) to be considered in the predictive modeling of exposure levels.  
Assessing exposures at critical time window(s) is essential for determining the true 
underlying relationship between exposure and disease.  
This study also contributes to the science on the health effects of organochlorines.  
This study does not provide evidence for an effect of relatively low level exposures to 
organochlorines on age at menopause.  However, it does not negate the potential for an effect 
at higher concentrations.  The study results demonstrate a strong effect for family history of 
early menopause before age 46 and ovary removal before age 40, in addition to the well-
established association between current smoking and earlier age at menopause.  Given that 
early menopause can increase the risk of infertility, heart disease, and osteoporosis, it would 
be important to investigate these factors further.     
 
6.5 Future directions 
This study was limited to the investigation of two serum organochlorine measures and 
an assumed exponential rate of decay.  Better assessment of the shape of the concentration 
curve could help to improve the prediction of organochlorine concentrations.  Multiple serial 
measures of DDE and PCBs, as well as their predictors, would be beneficial in this regard.  
The strong effect of body mass index, despite the general lack of obese individuals at 
baseline, provides us with clues to the important mechanisms underlying the maintenance 
and elimination of organochlorines.  Further investigations are warranted using a wider range 
of body mass index, with particular consideration for heavier or obese individuals.  
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Additionally, given the low variability in age and parity in this study, another question left 
unanswered is whether these factors have an effect on the rate of change in levels.  Future 
studies should also consider the dual role of fat in the metabolism and dilution of these 
organochlorines, as well as the variation in effect as lactation progresses.  While the 
predictors identified in this study explain a large portion of the variation in organochlorine 
concentrations over time, other potentially important factors, such as fish consumption, 
should be considered in future analyses.    
Given the importance of age at menopause on the risk of subsequent health outcomes, 
additional investigations are warranted with consideration of critical time window(s) of 
exposure.  Although we estimated levels at one common age of 40, there is potential 
heterogeneity between subjects in their etiologically relevant period of exposure.  Studies 
among populations with low level exposures as well higher level exposures would further 
elucidate the role of these organochlorines.  The large effect of family history of early 
menopause and unilateral oophorectomy also deserves further attention.  Understanding the 
genetic and environmental contributions to age at menopause would be important, as public 
health resources could be better targeted to address the needs of women faced with an earlier 
or later menopause.   
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